

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/12, 15/63, 5/10, C07K 14/715, G01N 33/68, A61K 31/00, 38/00</b>		<b>A1</b>	(11) International Publication Number: <b>WO 95/19436</b> (43) International Publication Date: <b>20 July 1995 (20.07.95)</b>
(21) International Application Number: <b>PCT/US95/00476</b> (22) International Filing Date: <b>11 January 1995 (11.01.95)</b> (30) Priority Data: <b>08/182,962 13 January 1994 (13.01.94) US</b> (60) Parent Application or Grant (63) Related by Continuation <b>US 08/182,962 (CIP) Filed on 13 January 1994 (13.01.94)</b> (71) Applicant (for all designated States except US): <b>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612-3550 (US).</b> (72) Inventors; and (75) Inventors/Applicants (for US only): <b>CHARO, Israel [US/US]; 224 Happy Hollow Court, Lafayette, CA 94549 (US). COUGHLIN, Sha [US/US]; 2 Turtle Rock Court, Tiburon, CA 9492 (US).</b>		(74) Agent: <b>BERLINER, Robert; Robbins, Berliner &amp; Carson, 5th floor, 201 N. Figueroa Street, Los Angeles, CA 90012-2628 (US).</b> (81) Designated States: <b>AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).</b>  <b>Published</b> <i>With international search report.</i>	
(54) Title: <b>MAMMALIAN MONOCYTE CHEMOATTRACTANT PROTEIN RECEPTORS</b>			
(57) Abstract  DNAs encoding human chemokine receptors, MCP-1R and MCP-1RB, and processes for expressing them are disclosed. The receptor proteins, which are the products of alternately spliced versions of the MCP-1R gene, may be used in an assay to identify antagonists of MCP-1. The antagonists are therapeutically useful in the treatment of atherosclerosis and other diseases characterized by monocyte infiltrates.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

1.

## MAMMALIAN MONOCYTE CHEMOATTRACTANT PROTEIN RECEPTORS

5 This invention relates to novel cytokine receptors that mediate the chemotaxis and activation of monocytes, to the DNA sequences encoding the receptors and to processes for obtaining the receptors and producing them by recombinant genetic engineering techniques. The novel receptors appear to arise via alternative splicing of the DNA sequences.

10 This invention was made with Government support under Grant Nos. RO1-HL42662 and RO1-HL43322 awarded by the National Institutes of Health. The Government has certain rights in this invention.

### BACKGROUND OF THE INVENTION

15 A growing family of regulatory proteins that deliver signals between cells of the immune system has been identified. Called cytokines, these proteins have been found to control the growth and development, and bioactivities, of cells of the hematopoietic and immune systems. Cytokines exhibit a wide range of biological activities with target cells from bone marrow, peripheral blood, fetal liver, and  
20 other lymphoid or hematopoietic organs. Exemplary members of the family include the colony-stimulating factors (GM-CSF, M-CSF, G-CSF, interleukin-3), the interleukins (IL-1, IL-2, IL-11), the interferons (alpha, beta and gamma), the tumor necrosis factors (alpha and beta) and erythropoietin.

Within this family of proteins, an emerging group of chemotactic cytokines,  
25 also called chemokines or intercrines, has been identified. These chemokines are basic, heparin-binding proteins that have proinflammatory and reparative activities. They are distinguished from other cytokines having proinflammatory and reparative activities (such as IL-1 and platelet-derived growth factor) by their characteristic conserved single open reading frames, typical signal sequences in the N-terminal  
30 region, AT rich sequences in their C-terminal untranslated regions, and rapidly inducible mRNA expression. See, e.g., Wolpe, FASEB J. 3:2565-73(1989) and

## 2.

Oppenheim, Ann. Rev. Immunol. 9:617-48(1991). Typically, the chemokines range in molecular mass from 8-10kD; in humans, they are the products of distinct genes clustered on chromosomes 4 and 17. All chemokines have four cysteine residues, forming two disulfide bridges.

5 Two subfamilies of chemokines have been recognized, based on chromosomal location and the arrangement of the cysteine residues. The human genes for the  $\alpha$ , or C-X-C, subfamily members are located on human chromosome 4. In this subfamily the first two cysteines are separated by one amino acid. The members of this subfamily, the human proteins IL-8 (interleukin-8), beta TG (beta  
10 thromboglobulin), PF-4 (platelet factor 4), IP-10, GRO (growth stimulating factor, also known as MGSF, melanoma grow stimulating factor) and murine MIP-2 (macrophage inhibitory protein-2), besides having the C-X-C arrangement of their first two cystein residues, exhibit homology in their amino acid sequences in the range of 30-50%.

15 In the beta subfamily, the first two cysteine residues are located adjacent to each other, a C-C arrangement. The human genes encoding the  $\beta$  subfamily proteins are located on chromosome 17 (their mouse counterparts are clustered on mouse chromosome 11 which is the counterpart of human chromosome 17). Homology in the beta subfamily ranges from 28-45% intraspecies, from 25-55%  
20 interspecies. Exemplary members include the human proteins MCP-1 (monocyte chemoattractant protein-1), LD-78  $\alpha$  and  $\beta$ , ACT-2 and RANTES and the murine proteins JE factor (the murine homologue of MCP-1), MIP-1 $\alpha$  and  $\beta$  (macrophage inhibitory protein-1) and TCA-3. Human MCP-1 and murine JE factor exert several effects specifically on monocytes. Both proteins are potent  
25 chemoattractants for human monocytes in vitro and can stimulate an increase in cytosolic free calcium and the respiratory burst in monocytes. MCP-1 has been reported to activate monocyte-mediated tumoricidal activity, as well as to induce tumoricidal activity. See, e.g., Rollins, Mol. and Cell. Biol. 11:3125-31(1991) and Walter, Int. J. Cancer 49:431-35(1991). MCP-1 has been implicated as an  
30 important factor in mediating monocytic infiltration of tissues inflammatory processes such as rheumatoid arthritis and alveolitis. See, e.g., Koch, J. Clin.

## 3.

Invest. 90:772-79(1992) and Jones, J. Immunol. 149:2147-54(1992). The factor may also play a fundamental role in the recruitment of monocyte-macrophages into developing atherosclerotic lesions. See e.g., Nelken, J. Clin. Invest. 88:1121-27(1991), Yla-Herttuala, Proc. Nat'l. Acad. Sci. USA 88:5252-56(1991) and  
5 Cushing, Proc. Natl. Acad. Sci. USA 87:5134-38(1990).

Many of these chemokines has been molecularly cloned, heterologously expressed and purified to homogeneity. Several have had their receptors cloned. Two highly homologous receptors for the C-X-C chemokine IL-8 have been cloned and were shown to belong to the superfamily of G protein-linked receptors  
10 containing seven transmembrane-spanning domains. See Holmes, Science 253:1278-80(1991) and Murphy, Science 253:1280-83(1991). More recently, a receptor for the C-C chemokines MIP-1 $\alpha$  and RANTES has been molecularly cloned and shown to belong to the same seven transmembrane-spanning receptor superfamily. See Gao, J. Exp. Med. 177:1421-27(1993) and Neote, Cell 72:415-  
15 25(1993). This receptor, which is believed to be involved with leukocyte activation and chemotaxis, exhibits varying affinity and signaling efficacy depending on the ligand. It binds with the highest affinity and the best signaling efficacy to human MIP-1 $\alpha$ . To MCP-1, the receptor exhibits high binding affinity relative to RANTES and huMIP-1 $\beta$  but transmits signal with lower efficacy. See  
20 Neote, Id., at 421-22. Although pharmacology studies predicted the existence of a specific MCP-1 receptor, and the chemokine receptors already cloned could not account for the robust responses of monocytes to MCP-1, to date no specific receptor for MCP-1 has been reported. See Wang, J. Exp. Med. 177:699-705(1993) and Van Riper, J. Exp. Med. 177:851-856(1993). The difficulty may  
25 arise at least in part from the fact that in the chemokine family individual receptors may or may not bind multiple ligands, making functional sorting, tracking and identification impractical. It has also been speculated that the receptor members of the family may not share structural features -- to account for why the MCP-1 receptor has to date eluded researchers. See Edgington, Bio/Technology II:676-  
30 81(1993).

4.

There remains a need in the art for additional receptors to these chemokines. There also remains a need in the art for receptors specific for each of the C-C proteins, especially a receptor specific to MCP-1. Without a specific receptor to MCP-1, there is no practical way to develop assays of MCP-1 binding to its receptor. The availability of such assays provides a powerful tool for the discovery of antagonists of the MCP-1/ MCP-1 receptor interaction. Such antagonists would be excellent candidates for therapeutics for the treatment of atherosclerosis in tumor growth suppression and in other diseases characterized by monocytic infiltrates such as rheumatoid arthritis and alvcolitis.

10

#### SUMMARY OF THE INVENTION

In one aspect the invention provides novel human chemokine receptor proteins MCP-1RA and MCP-1RB, which are substantially free from other mammalian proteins with which they are typically found in their native state. MCP-1RA and MCP-1RB are identical in amino acid sequence (SEQ ID NO:2 and SEQ ID NO:4) from the 5' untranslated region through the putative seventh transmembrane domain, but they have different cytoplasmic tails. Hence they appear to represent alternatively spliced version of the MCP-1 gene. The proteins may be produced by recombinant genetic engineering techniques. They may additionally be purified from cellular sources producing the factor constitutively or upon induction with other factors. They may also be synthesized by chemical techniques. One skilled in the art could apply a combination of the above-identified methodologies to synthesize the factor.

Active mature MCP-1RA is an approximately 374 amino acid protein having a predicted molecular weight for the mature protein of about 42,000 daltons. Its alternatively spliced version, MCP-1RB, is an approximately 360 amino acid protein having a molecular weight of about 41,000 daltons. The MCP-1R proteins of this invention display high specificity for MCP-1 when expressed in *Xenopus* oocytes.

Another aspect of this invention is DNA sequences (SEQ ID NO:1 and SEQ ID NO:3) that encode the expression of the MCP-1RA and 1RB proteins. These

## 5.

DNA sequences may include an isolated DNA sequence that encodes the expression of a MCP-1R protein as described above. As used here, "isolated" means substantially free from other mammalian DNA or protein sequences with which the subject DNA or protein sequence is typically found in its native, i.e., endogenous, state. The DNA sequences coding for active MCP-1RA and 1RB are characterized as comprising the same or substantially the same nucleotide sequence as in Figures 1 and 2 (SEQ ID NOS: 1 and 3), respectively, or active fragments thereof. The DNA sequences may include 5' and 3' non-coding sequences flanking the coding sequence. The DNA sequences may also encode an amino terminal signal peptide. Figures 1 and 2 illustrate the non-coding 5' and 3' flanking sequences and a signal sequence of the MCP-1RA and 1RB sequences, respectively, isolated from the human monocytic cell line MonoMac 6 and expressed in *Xenopus* oocytes.

It is understood that the DNA sequences of this invention may exclude some or all of these signal and/or flanking sequences. In addition, the DNA sequences of the present invention encoding a biologically active human MCP-1R protein may also comprise DNA capable of hybridizing under appropriate stringency conditions, or which would be capable of hybridizing under such conditions but for the degeneracy of the genetic code, to an isolated DNA sequence of Figure 1 or Figure 2 (SEQ ID NOS: 1 and 3). Accordingly, the DNA sequences of this invention may contain modifications in the non-coding sequences, signal sequences or coding sequences, based on allelic variation, species variation or deliberate modification. Additionally, analogs of MCP-1R are provided and include truncated polypeptides, e.g., mutants in which there are variations in the amino acid sequence that retain biological activity, as defined below, and preferably have a homology of at least 80%, more preferably 90%, and most preferably 95%, with the corresponding region of the MCP-1R sequences of Figure 1 or Figure 2 (SEQ ID NOS: 2 and 4). Examples include polypeptides with minor amino acid variations from the native amino acid sequences of MCP-1R of Figures 1 and 2 (SEQ ID NOS: 2 and 4); in particular, conservative amino acid replacements. Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Genetically encoded amino acids are generally divided into four families:

6.

(1) acidic = aspartate, glutamate; (2) basic = lysine, arginine, histidine; (3) non-polar = alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar = glycine, asparagine, glutamine, cystine, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes  
5 classified jointly as aromatic amino acids. For example, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar conservative replacement of an amino acid with a structurally related amino acid will not have a major effect on activity or functionality.

10 Using the sequences of Figure 1 and Figure 2 (SEQ ID NOS: 1, 2, 3 and 4) as well as the denoted characteristics of a MCP-1R receptor molecule in general, it is within the skill in the art to obtain other polypeptides or other DNA sequences encoding MCP-1R. For example, the structural gene can be manipulated by varying individual nucleotides, while retaining the correct amino  
15 acid(s), or varying the nucleotides, so as to modify the amino acids, without loss of activity. Nucleotides can be substituted, inserted, or deleted by known techniques, including, for example, in vitro mutagenesis and primer repair. The structural gene can be truncated at its 3'-terminus and/or its 5'-terminus while retaining its activity. For example, MCP-1RA and MCP-1RB as encoded in  
20 Figure 1 and Figure 2 (SEQ ID NOS: 1 and 2; SEQ ID NOS: 3 and 4) respectively, contain N-terminal regions which it may be desirable to delete. It also may be desirable to remove the region encoding the signal sequence, and/or to replace it with a heterologous sequence. It may also be desirable to ligate a portion of the MCP-1R sequences (SEQ ID NOS: 1 and 3), particularly that which includes the  
25 amino terminal domain to a heterologous coding sequence, and thus to create a fusion peptide with the receptor/ligand specificity of MCP-1RA or MCP-1RB.

In designing such modifications, it is expected that changes to nonconserved regions of the MCP-1R sequences (SEQ ID NOS: 1, 2, 3 and 4) will have relatively smaller effects on activity, whereas changes in the conserved regions,  
30 and particularly in or near the amino terminal domain are expected to produce larger effects. The comparison among the amino acid sequences of MCP-1RA and



7.

1RB (SEQ ID NOS:2 and 4), the MIP-1 $\alpha$ /RANTES receptor (SEQ ID NO:5), the orphan receptor HUMSTR (SEQ ID NO:6) and the two IL-8 receptors (SEQ ID NOS: 7 and 8), as illustrated in Figure 4, provides guidance on amino acid substitutions that are compatible with receptor activity. Amino acid residues that are conserved among the MCP-1R sequences (SEQ ID NOS: 2 and 4) and at least two of the other sequences (SEQ ID NOS:5, 6, 7 and 8) are not expected to be candidates for substitution. A residue which shows conservative variations among the MCP-1R sequences and at least two of the other sequences is expected to be capable of similar conservative substitution of the MCP-1R sequences. Similarly, a residue which varies nonconservatively among the MCP-1R sequences and at least three of the other sequences is expected to be capable of either conservative or nonconservative substitution. When designing substitutions to the MCP-1R sequences, replacement by an amino acid which is found in the comparable aligned position of one of the other sequences is especially preferred.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Molecular Cloning: A Laboratory Manual, Second Edition (1989); DNA Cloning, Volumes I and II (D. N. Glover, Ed. 1985); Oligonucleotide Synthesis (M. J. Gait, Ed. 1984); Nucleic Acid Hybridization (B. D. Hames and S. J. Higgins, Eds. 1984); Transcription and Translation (B. D. Hames and S. J. Higgins, Eds. 1984); Animal Cell Culture (R. I. Freshney, Ed. 1986); Immobilized Cells and Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide to Molecular Cloning (1984); the series, Methods in Enzymology (Academic Press, Inc.); Gene Transfer Vectors for Mammalian Cells (J. H. Miller and M. P. Calos, Eds. 1987, Cold Spring Harbor Laboratory), Methods in Enzymology, Volumes 154 and 155 (Wu and Grossman, and Wu, Eds., respectively), (Mayer and Walker, Eds.) (1987); Immunochemical Methods in Cell and Molecular Biology (Academic Press, London), Scopes, (1987); Protein Purification: Principles and Practice, Second Edition (Springer-Verlag, N.Y.); and Handbook of Experimental Immunology, Volumes

8.

I-IV (D. M. Weir and C. C. Blackwell, Eds 1986). All patents, patent applications, and publications mentioned herein, both *supra* and *infra*, are hereby incorporated by reference.

5 Additionally provided by this invention is a recombinant DNA vector comprising vector DNA and a DNA sequence (SEQ ID NOS: 1 and 3) encoding a mammalian MCP-1R polypeptide. The vector provides the MCP-1R DNA in operative association with a regulatory sequence capable of directing the replication and expression of an MCP-1R protein in a selected host cell. Host cells transformed with such vectors for use in expressing recombinant MCP-1R proteins  
10 are also provided by this invention. Also provided is a novel process for producing recombinant MCP-1R proteins or active fragments thereof. In this process, a host cell line transformed with a vector as described above containing a DNA sequence (SEQ ID NOS: 1 and 3) encoding expression of an MCP-1R protein in operative association with a suitable regulatory sequence capable of  
15 directing replication and controlling expression of an MCP-1R protein is cultured under appropriate conditions permitting expression of the recombinant DNA. The expressed protein is then harvested from the host cell or culture medium using suitable conventional means. This novel process may employ various known cells as host cell lines for expression of the protein. Currently preferred cell lines are  
20 mammalian cell lines and bacterial cell lines.

This invention also provides compositions for use in therapy, diagnosis, assay of MCP-1R, or in raising antibodies to MCP-1R, comprising effective amounts of MCP-1R proteins prepared according to the foregoing processes. Another aspect of this invention provides an assay to assess MCP-1 binding, useful  
25 in screening for specific antagonists of the MCP-1 receptor. Such assay comprises the steps of expression and isolation of the recombinant MCP-1 receptor(s) and/or their extracellular domains and the development of a solid-phase assay for MCP-1 binding. The availability of such assays, not heretofore available, permits the development of therapeutic antagonists, useful in the treatment of atherosclerosis  
30 and other diseases characterized by monocytic infiltrates.

9.

A further aspect of the invention therefore are pharmaceutical compositions containing a therapeutically effective amount of an MCP-1 antagonist identified using the assays of this invention. Such MCP-1 antagonist compositions may be employed in therapies for atherosclerosis, cancer and other diseases characterized by monocytic infiltrates. An additional aspect therefore, the invention includes a method for treating these and/or other diseases and pathological states by administering to a patient a therapeutically effective amount of MCP-1 antagonist, or an active fragment thereof, in a suitable pharmaceutical carrier.

Other aspects and advantages of this invention are described in the following detailed description.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates the human cDNA and amino acid sequences (SEQ ID NO:1 and SEQ ID NO:2, respectively) of the isolated MCP-1 receptor clone, MCP-1RA.

FIG. 2 illustrates the human cDNA and amino acid sequences (SEQ ID NO:3 and SEQ ID NO:4, respectively) of the isolated MCP-1 receptor clone, MCP-1RB.

FIG. 3 illustrates the results of Northern blot analysis of hematopoietic cell lines that were probed for MCP-1RA and MCP-1RB mRNA.

FIG. 4 illustrates the predicted amino acid sequence of the MCP-1 receptor A (MCP-1RA) (SEQ ID NO:2), aligned with the MIP-1 $\alpha$ /RANTES receptor sequence (SEQ ID NO:5), the orphan receptor sequence HUMSTSR (SEQ ID NO:6) and the two IL-8 receptor sequences (SEQ ID NOS:7 and 8). Identical residues are boxed. The seven putative transmembrane domains are indicated by the horizontal bars. Gaps inserted to optimize the alignments are indicated by dashes. Amino acid numbers for each sequence are located to the right of the sequences.

10.

FIG. 5 graphically depicts the functional expression of MCP-1R protein in *Xenopus* oocytes as assayed by measuring calcium mobilization in the presence of MCP-1.

FIG. 6 graphically depicts the results of the calcium efflux assay used to  
5 confirm gene expression and responsiveness to MCP-1 as described in Example 4.

FIG. 7 graphically depicts the binding of  $^{125}\text{I}$ -MCP-1 to the recombinant MCP-1RB receptor, as described in detail in Example 5.

FIG. 8 graphically depicts the results of the MCP-1RB receptor-mediated calcium mobilization experiments also described in detail in Example 5. 8A  
10 depicts intracellular calcium flux as a function of MCP-1 concentration (nM). Calcium transients peaked at 4-8 sec. after addition of MCP-1 and returned to baseline within 90 sec. of activation. 8B depicts the MCP-1 stimulated calcium mobilization ( $\text{EC}_{50} = 3.4 \text{ nM}$ ) and the lack of stimulated calcium mobilization by other cytokines. 8C illustrates that MCP-1 desensitized the cells to a second  
15 addition of MCP-1.

## DETAILED DESCRIPTION

### I. Introduction

20 This invention provides biologically active human chemokine receptors, MCP-1RA and 1RB, substantially free from association with other mammalian proteins and proteinaceous material with which they are normally associated in its native state. MCP-1R proteins can be produced by recombinant techniques to enable production in large quantities useful for assaying potential antagonists to  
25 identify candidates for therapeutics for the treatment of atherosclerosis and other monocytic associated diseases such as cancer and rheumatoid arthritis. Alternatively, MCP-1R proteins may be obtained as a homogeneous protein purified from a mammalian cell line secreting or expressing it, or they may be chemically synthesized.

30 Human MCP-1RA was isolated from a derivative of a human monocytic leukemia cell line, MonoMac 6 (MM6). Because monocytes are difficult to isolate

11.

in large quantities and express less than 2000 high-affinity binding sites per cell, a cell line that responded well to MCP-1 was needed. Because of their consistency in response, the MM6 cell line was chosen. It can be obtained from the DSM German Collection of Microorganisms and Cell Cultures (Mascheroder Weglb, 3300 Braunschweig, Germany); see also, Ziegler-Heitbrock, Int. J. Cancer 41:456(1988). Cells were grown in appropriate medium and then tested for changes in intracellular calcium in response to MCP-1 and other chemokines. A cDNA library was prepared from MonoMac 6 mRNA according to methods previously described. See Vu, Cell 64:1057-68(1991). A polymerase chain reaction (PCR)-based strategy using degenerate oligonucleotide primers corresponding to conserved sequences in the second and third transmembrane domains of the other chemokine receptors and in the HUMSTSR orphan receptor was employed (See SEQ ID NOS: 5, 6, 7 and 8). Amplification of cDNA derived from MM6 cells using the primers yielded a number of PCR products corresponding in size to those expected for a seven-transmembrane receptor. Analysis of the subcloned PCR products revealed cDNAs encoding the predicted arrangements of the receptors upon which the primers were designs, along with one cDNA that appeared to encode a novel receptor.

To obtain a full-length version of this clone, an MM6 cDNA library was constructed and probed with the PCR product. An isolated clone of 2.1kb was obtained and called MCP-1RA. FIG. 1 illustrates the cDNA sequence (SEQ ID NO:1) and the predicted amino acid sequence (SEQ ID NO:2) of the clone. The nucleotide sequence (SEQ ID NO:1) comprises 2232 base pairs, including a 5' noncoding sequence of 39 base pairs and a 3' noncoding sequence of 1071 base pairs. The MCP-1RA sequence is characterized by a single long open reading frame encoding a 374 amino acid following the initiation methionine at position 23.

The nucleotide sequence of MCP-1RA cDNA (SEQ ID NO:1) was compared with the nucleotide sequences recorded in Genbank. Homology was found with the coding sequences of the receptors for MIP-1 alpha/RANTES, the HUMSTSR orphan receptor and IL-8 (SEQ ID NOS: 5, 6, 7 and 8, respectively).

12.

No significant homology was found between the coding sequence of MCP-1RA and any other published polypeptide sequence.

The predicted amino acid sequence of MCP-1RA (SEQ ID NO:2) reveals seven putative transmembrane domains and an extracellular amino terminus of 40  
5 residues. Further analysis of the MCP-1RA amino acid sequence reveals several interesting features. Despite its homology with the related MIP-1 alpha/RANTES receptor and the IL-8 receptors, MCP-1RA exhibits significant divergence in its amino and carboxyl termini. See FIG. 4 (SEQ ID NOS: 2, 5, 6, 7 and 8). Additionally, a striking identity between MCP-1RA and the MIP-1 alpha/RANTES  
10 receptor occurs in a 31 amino acid sequence beginning with the septate IFFIILL at the end of the third transmembrane domain.

Preliminary biological characterization indicates that MCP-1RA confers robust and remarkable specific responses to nanomolar concentrations of MCP-1. Surprisingly, no response was elicited by the MIP-1 $\alpha$ , MIP-1 $\beta$ , RANTES or IL-8,  
15 even at concentrations of 500 nanomoles.

Analysis of additional clones in the MM6 cDNA library revealed a second sequence, identical to the MCP-1RA sequence from the 5' untranslated region through the putative seventh transmembrane domain but containing a different cytoplasmic tail. This second sequence (SEQ ID NOS:3 and 4), termed MCP-  
20 1RB, appears to be an alternatively spliced version of MCP-1RA. It is further characterized below.

The MCP-1R polypeptides provided herein also include polypeptides encoded by sequences similar to that of MCP-1RA and 1RB (SEQ ID NOS: 1, 2, 3 and 4) in FIGS. 1 and 2, but into which modifications are naturally provided or  
25 deliberately engineered. This invention also encompasses such novel DNA sequences, which code on expression for MCP-1R polypeptides having specificity for the MCP-1 receptor. These DNA sequences include sequences substantially the same as the DNA sequences (SEQ ID NOS: 1 and 3) of FIGS. 1 and 2 and biologically active fragments thereof, and such sequences that hybridize under  
30 stringent hybridization conditions to the DNA sequences (SEQ ID NOS: 1 and 3) of FIGS. 1 and 2. See Maniatis, Molecular Cloning (A Laboratory Manual), Cold

13.

Spring Harbor Laboratory (1982), pages 387-389. One example of such stringent conditions is hybridization at 4 X SSC, at 65 degrees C, followed by a washing in 0.1 X SSC at 65 degrees C for one hour. Another exemplary stringent hybridization scheme uses 50% formamide, 4 X SSC at 42 degrees C.

- 5 DNA sequences that code for MCP-1R polypeptides but differ in codon sequence due to the degeneracies inherent in the genetic code are also encompassed by this invention. Allelic variations, i.e., naturally occurring interspecies base changes that may or may not result in amino acid changes, in the MCP-1R DNA sequences (SEQ ID NOS: 1 and 3) of FIGS. 1 and 2 encoding MCP-1R  
10 polypeptides having MCP-1R activity (for example, specificity for the MCP-1 receptor) are also included in this invention.

## II. Modes for Carrying Out the Invention

- Methods for producing a desired mature polypeptide can include the  
15 following techniques. First, a vector coding for a MCP-1R polypeptide can be inserted into a host cell, and the host cell can be cultured under suitable culture conditions permitting production of the polypeptide.

- The MCP-1R genes or fragments thereof can be expressed in a mammalian, insect, or microorganism host. The polynucleotides encoding MCP-1R genes are  
20 inserted into a suitable expression vector compatible with the type of host cell employed and is operably linked to the control elements within that vector. Vector construction employs techniques which are known in the art. Site-specific DNA cleavage involved in such construction is performed by treating with suitable restriction enzymes under conditions which generally are specified by the  
25 manufacturer of these commercially available enzymes.

A suitable expression vector is one that is compatible with the desired function (e.g., transient expression, long term expression, integration, replication, amplification) and in which the control elements are compatible with the host cell.

14.

A. Expression in mammalian cells

Vectors suitable for replication in mammalian cells are known in the art, and can include viral replicons, or sequences that ensure integration of the sequence encoding MCP-1R into the host genome. Exemplary vectors include those derived  
5 from simian virus SV40, retroviruses, bovine papilloma virus, vaccinia virus, and adenovirus.

As is known in the art, the heterologous DNA, in this case MCP-1R DNA, is inserted into the viral genome using, for example, homologous recombination techniques. The insertion is generally made into a gene which is non-essential in  
10 nature, for example, the thymidine kinase gene (tk), which also provides a selectable marker. Plasmid shuttle vectors that greatly facilitate the construction of recombinant viruses have been described (see, for example, Mackett, et al. (1984); Chakrabarti, et al. (1985); Moss (1987)). Expression of the heterologous polypeptide then occurs in cells or individuals which are immunized with the live  
15 recombinant virus.

Such suitable mammalian expression vectors usually contain a promoter to mediate transcription of foreign DNA sequences and, optionally, an enhancer. Suitable promoters for mammalian cells are known in the art and include viral promoters such as that from simian virus 40 (SV40), cytomegalovirus (CMV),  
20 Rous sarcoma virus (RSV), adenovirus (ADV), and bovine papilloma virus (BPV).

The optional presence of an enhancer, combined with the promoter described above, will typically increase expression levels. An enhancer is any regulatory DNA sequence that can stimulate transcription up to 1000-fold when linked to endogenous or heterologous promoters, with synthesis beginning at the normal  
25 mRNA start site. Enhancers are also active when placed upstream or downstream from the transcription initiation site, in either normal or flipped orientation, or at a distance of more than 1000 nucleotides from the promoter. See Maniatis, Science 236:1237(1987), Alberts, Molecular Biology of the Cell, 2nd Ed. (1989). Enhancer elements derived from viruses may be particularly useful, because they  
30 typically have a broader host range. Examples useful in mammalian cells include the SV40 early gene enhancer (see Dijkema, EMBO J. 4:761(1985)) and the



15.

enhancer/promoters derived from the long terminal repeat (LTR) of the RSV (see Gorman, Proc. Natl. Acad. Sci. 79:6777(1982b)) and from human cytomegalovirus (see Boshart, Cell 41:521(1985)). Additionally, some enhancers are regulatable and become active only in the presence of an inducer, such as a hormone or metal ion (see Sassone-Corsi and Borelli, Trends Genet. 2:215(1986)); Maniatis, Science 236:1237(1987)).

In addition, the expression vector can and will typically also include a termination sequence and poly(A) addition sequences which are operably linked to the MCP-1R coding sequence.

Sequences that cause amplification of the gene may also be desirably included in the expression vector or in another vector that is co-translated with the expression vector containing an MCP-1R DNA sequence, as are sequences which encode selectable markers. Selectable markers for mammalian cells are known in the art, and include for example, thymidine kinase, dihydrofolate reductase (together with methotrexate as a DHFR amplifier), aminoglycoside phosphotransferase, hygromycin B phosphotransferase, asparagine synthetase, adenosine deaminase, metallothionein, and antibiotic resistant genes such as neomycin.

The vector that encodes an MCP-1R polypeptide can be used for transformation of a suitable mammalian host cell. Transformation can be by any known method for introducing polynucleotides into a host cell, including, for example packaging the polynucleotide in a virus and transducing a host cell with the virus. The transformation procedure used depends upon the host to be transformed. Methods for introduction of heterologous polynucleotides into mammalian cells are known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to Chinese hamster ovary (CHO)

16.

cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), and a number of other cell lines.

5     **B.     Expression in Insect Cells**

In the case of expression in insect cells, generally the components of the expression system include a transfer vector, usually a bacterial plasmid, which contains both a fragment of the baculovirus genome, and a convenient restriction site for insertion of the heterologous gene or genes to be expressed; a wild type  
10    baculovirus with a sequence homologous to the baculovirus-specific fragment in the transfer vector (this allows for the homologous recombination of the heterologous gene in to the baculovirus genome); and appropriate insect host cells and growth media.

Exemplary transfer vectors for introducing foreign genes into insect cells include

15    pAc373 and pVL985. See Luckow and Summers, Virology 17:31(1989).

The plasmid usually also contains the polyhedron polyadenylation signal and a procaryotic ampicillin-resistance (amp) gene and origin of replication for selection and propagation in E. coli. See Miller, Ann. Rev. Microbiol. 42:177(1988).

Baculovirus transfer vectors usually contain a baculovirus promoter, i.e., a DNA  
20    sequence capable of binding a baculovirus RNA polymerase and initiating the downstream (5' to 3') transcription of a coding sequence (e.g., structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region typically includes an RNA polymerase binding site and a transcription  
25    initiation site. A baculovirus transfer vector can also have an enhancer, which, if present, is usually distal to the structural gene. Expression can be either regulated or constitutive.

**C.     Expression in Microorganisms - Yeast and Bacteria**

30    Fungal expression systems can utilize both yeast and filamentous fungi hosts. Examples of filamentous fungi expression systems are Aspergillus, as described in

17.

EP Patent Pub. No. 357 127 (published March 7, 1990), and Acremonium Chrysogenum, described in EP Patent Pub. No. 376 266 (published July 4, 1990).

A yeast expression system can typically include one or more of the following:  
a promoter sequence, fusion partner sequence, leader sequence, transcription  
5 termination sequence.

A yeast promoter, capable of binding yeast RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA, will have a transcription initiation region usually placed proximal to the 5' end of the coding sequence. This transcription initiation region typically  
10 includes an RNA polymerase binding site (a "TATA Box") and a transcription initiation site. The yeast promoter can also have an upstream activator sequence, usually distal to the structural gene. The activator sequence permits inducible expression of the desired heterologous DNA sequence. Constitutive expression occurs in the absence of an activator sequence. Regulated expression can be either  
15 positive or negative, thereby either enhancing or reducing transcription.

Particularly useful yeast promoter sequences include alcohol dehydrogenase (ADH) (EP Patent Pub. No. 284 044), enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehyde-3-phosphate-dehydrogenase (GAP or GAPDH), hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, and pyruvate kinase  
20 (PyK)(EP Patent Pub. No. 329 203). The yeast PHO5 gene, encoding acid phosphatase, also provides useful promoter sequences. See Myanohara, Proc. Natl. Acad. Sci. USA80:1(1983).

An MCP-1R gene or an active fragment thereof can be expressed intracellularly in yeast. A promoter sequence can be directly linked with an MCP-1R gene or  
25 fragment, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus can be cleaved from the protein by *in vitro* incubation with cyanogen bromide.

Intracellularly expressed fusion proteins provide an alternative to direct  
30 expression of an MCP-1R sequence. Typically, a DNA sequence encoding the N-terminal portion of a stable protein, a fusion partner, is fused to the 5' end of

18.

heterologous DNA encoding the desired polypeptide. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the yeast or human superoxide dismutase (SOD) gene, can be linked at the 5' terminus of an MCP-1R sequence and expressed in yeast. The DNA sequence at the  
5 junction of the two amino acid sequences may or may not encode a cleavable site. See, e.g., EP Patent Pub. No. 196 056. Alternatively, MCP-1R polypeptides can also be secreted from the cell into the growth media by creating a fusion protein comprised of a leader sequence fragment that provides for secretion in yeast or bacteria of the MCP-1R polypeptides. Preferably, there are processing sites  
10 encoded between the leader fragment and the MCP-1R sequence (SEQ ID NOS: 1 and 3) that can be cleaved either *in vivo* or *in vitro*. The leader sequence fragment typically encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. DNA encoding suitable signal sequences can be derived from genes for secreted yeast proteins, such as the  
15 yeast invertase gene (EP Patent Pub. No. 12 873) and the A-factor gene (U.S. Patent No. 4,588,684). Alternatively, leaders of non-yeast origin, such as an interferon leader, can be used to provide for secretion in yeast (EP Patent Pub. No. 60057). Transcription termination sequences recognized by yeast are regulatory regions located 3' to the translation stop codon. Together with the promoter they  
20 flank the desired heterologous coding sequence. These flanking sequences direct the transcription of an mRNA which can be translated into the MCP-1R polypeptide encoded by the MCP-1R DNA.

Typically, the above described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are  
25 put together in plasmids capable of stable maintenance in a host, such as yeast or bacteria. The plasmid can have two replication systems, so it can be maintained as a shuttle vector, for example, in yeast for expression and in a procaryotic host for cloning and amplification. Examples of such yeast-bacteria shuttle vectors include YEp24 (see Botstein, Gene 8:17-24 (1979)), pCI/1 (see Brake, Proc. Natl.  
30 Acad. Sci. USA 81:4642-4646(1984)), and YRp17 (see Stinchcomb, J. Mol. Biol. 158:157(1982)). In addition, the plasmid can be either a high or low copy number

19.

plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and typically about 10 to about 150. A host containing a high copy number plasmid will preferably have at least about 10, and more preferably at least about 20. Either a high or low copy number vector may be  
5 selected, depending upon the effect on the host of the vector and the MCP-1R polypeptides. See, e.g., Brake, et al., supra.

Alternatively, the expression constructs can be integrated into the yeast genome with an integrating vector. Integrating vectors typically contain at least one sequence homologous to a yeast chromosome that allows the vector to integrate,  
10 and preferably contain two homologous sequences flanking the expression construct. See Orr-Weaver, Methods In Enzymol. 101:228-245(1983) and Rine, Proc. Natl. Acad. Sci. USA 80:6750(1983).

Typically, extrachromosomal and integrating expression vectors can contain selectable markers to allow for the selection of yeast strains that have been  
15 transformed. Selectable markers can include biosynthetic genes that can be expressed in the yeast host, such as ADE2, HIS4, LEU2, TRP1, and ALG7, and the G418 resistance gene, which confer resistance in yeast cells to tunicamycin and G418, respectively. In addition, a suicide selectable marker can also provide yeast with the ability to grow in the presence of toxic compounds, such as metal. For  
20 example, the presence of CUP1 allows yeast to grow in the presence of copper ions. See Butt, Microbiol. Rev. 51:351(1987).

Alternatively, some of the above described components can be put together into transformation vectors. Transformation vectors are typically comprised of a selectable marker that is either maintained in a replicon or developed into an  
25 integrating vector, as described above.

Expression and transformation vectors, either extrachromosomal or integrating, have been developed for transformation into many yeasts. Exemplary yeasts cell lines are Candida albicans (Kurtz, Mol. Cell. Biol. 6:142(1986), Candida maltosa (Kunze, J. Basic Microbiol. 25:141(1985), Hansenula polymorpha (Gleeson, J. Gen. Microbiol. 132:3459(1986) and Roggenkamp, Mol. Gen. Genet. 202:302(1986), Kluyveromyces fragilis (Das, J. Bacteriol. 158:1165(1984),  
30

20.

Kluyveromyces lactis (De Louvencourt, J. Bacteriol. 154:737(1983) and Van den Berg, Bio/Technology 8:135(1990), Pichia guillermondii (Kunze, J. Basic Microbiol. 25:141(1985), Pichia pastoris (Cregg, Mol. Cell. Biol. 5:3376 (1985), Saccharomyces cerevisiae (Hinnen, PROC. NATL. ACAD. SCI. USA 5 75:1929(1978) and Ito, J. Bacteriol. 153:163(1983), Schizosaccharomyces pombe (Beach and Nurse, Nature 300:706(1981), and Yarrowia lipolytica (Davidow, Curr. Genet. 10:380471(1985) and Gaillardin, Curr. Genet. 10:49(1985).

Methods of introducing exogenous DNA into yeast hosts are well-known in the art, and typically include either the transformation of spheroplasts or of intact yeast 10 cells treated with alkali cations. Transformation procedures usually vary with the yeast species to be transformed. See the publications listed in the foregoing paragraph for appropriate transformation techniques.

Additionally, the MCP-1R gene or fragment thereof can be expressed in a bacterial system. In such system, a bacterial promoter is any DNA sequence 15 capable of binding bacterial RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. a desired heterologous gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region typically includes an RNA polymerase binding site and a transcription initiation 20 site. A bacterial promoter can also have a second domain called an operator, that can overlap an adjacent RNA polymerase binding site at which RNA synthesis begins. The operator permits negative regulated (inducible) transcription, as a gene repressor protein can bind the operator and thereby inhibit transcription of a specific gene. Constitutive expression can occur in the absence of negative 25 regulatory elements, such as the operator. In addition, positive regulation can be achieved by a gene activator protein binding sequence, which, if present is usually proximal (5') to the RNA polymerase binding sequence. An example of a gene activator protein is the catabolite activator protein (CAP), which helps initiate transcription of the lac operon in Escherichia coli (E. coli). See Raibaud, Ann. 30 Rev. Genet. 18:173(1984). Regulated expression can therefore be either positive or negative, thereby either enhancing or reducing transcription.

21.

Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose (lac) (see Chang, Nature 198:1056(1977), and maltose. Additional examples include promoter sequences  
5 derived from biosynthetic enzymes such as tryptophan (trp) (see Goeddel, NUC. ACIDS RES. 8:4057(1981), Yelverton, Nuc. Acids Res. 9:731(1981), U.S. Patent No. 4,738,921 and EP Patent Pub. Nos. 36 776 and 121 775). The  $\beta$ -lactomase (bla) promoter system (see Weissmann, Interferon 3 (ed. I. Gresser), the bacteriophage lambda PL promoter system (see Shimatake, Nature 292:128(1981))  
10 and the T5 promoter system (U.S. Patent No. 4,689,406) also provides useful promoter sequences.

In addition, synthetic promoters which do not occur in nature also function as bacterial promoters. For example, transcription activation sequences of one bacterial or bacteriophage promoter can be joined with the operon sequences of  
15 another bacterial or bacteriophage promoter, creating a synthetic hybrid promoter such as the tac promoter (see U.S. Patent No. 4,551,433, Amann, Gene 25:167(1983) and de Boer, Proc. Natl. Acad. Sci. 80:21(1983)). A bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. A  
20 naturally occurring promoter of non-bacterial origin can be coupled with a compatible RNA polymerase to produce high levels of expression of some genes in prokaryotes. The bacteriophage T7 RNA polymerase/promoter system is exemplary. (see Studier, J. Mol. Biol. 189:113(1986) and Tabor, Proc. Natl. Acad. Sci. 82:1074(1985)).

25 In addition to a functioning promoter sequence, an efficient ribosome binding site is also useful for the expression of the MCP-1R gene or fragment thereof in prokaryotes. In E. coli, the ribosome binding site is called the Shine-Dalgarno (SD) sequence and includes an initiation codon (ATG) and a sequence 3-9 nucleotides in length located 3-11 nucleotides upstream of the initiation codon (see  
30 Shine, Nature 254:34(1975)). The SD sequence is thought to promote binding of mRNA to the ribosome by the pairing of bases between the SD sequence and the

22.

3' and of E. coli 16S rRNA (see Steitz, Biological Regulation and Development: Gene Expression (ed. R.F. Goldberger)(1979)).

MCP-1R protein can be expressed intracellularly. A promoter sequence can be directly linked with an MCP-1R gene or a fragment thereof, in which case the first  
5 amino acid at the N-terminus will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus can be cleaved from the protein by *in vitro* incubation with cyanogen bromide or by either *in vivo* or *in vitro* incubation with a bacterial methionine N-terminal peptidase. See EP Patent Pub. No. 219 237.

10 Fusion proteins provide an alternative to direct expression. Typically, a DNA sequence encoding the N-terminal portion of an endogenous bacterial protein, or other stable protein, is fused to the 5' end of heterologous MCP-1R coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the bacteriophage lambda cell gene can be linked  
15 at the 5' terminus of an MCP-1R gene or fragment thereof and expressed in bacteria. The resulting fusion protein preferably retains a site for a processing enzyme (factor Xa) to cleave the bacteriophage protein from the MCP-1R gene or fragment thereof (see Nagai, Nature 309:810(1984). Fusion proteins can also be made with sequences from the lacZ gene (Jia, Gene 60:197(1987), the trpE gene  
20 (Allen, J. Biotechnol. 5:93(1987) and Makoff, J. Gen. Microbiol. 135:11(1989), and the Chey gene (EP Patent Pub. No. 324 647) genes. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme  
25 (e.g., ubiquitin specific processing-protease) to cleave the ubiquitin from the MCP-1R polypeptide. Through this method, mature MCP-1R polypeptides can be isolated. See Miller, Bio/Technology 7:698(1989).

Alternatively, MCP-1R polypeptides can also be secreted from the cell by creating chimeric DNA molecules that encode a fusion protein comprised of a  
30 signal peptide sequence fragment that provides for secretion of the MCP-1R polypeptides in bacteria. (See, for example, U.S. Patent No. 4,336,336). The



23.

signal sequence fragment typically encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). Preferably there are processing sites, which can be cleaved either in vivo or in vitro encoded between the signal peptide fragment and the MCP-1R polypeptide.

DNA encoding suitable signal sequences can be derived from genes for secreted bacterial proteins, such as the E. coli outer membrane protein gene (ompA) (Masui, Experimental Manipulation of Gene Expression (1983) and Ghayeb, EMBO J. 3:2437(1984)) and the E. coli alkaline phosphatase signal sequence (phoA) (see Oka, Proc. Natl. Acad. Sci. 82:7212(1985)). The signal sequence of the alpha-amylase gene from various Bacillus strains can be used to secrete heterologous proteins from E. subtilis (see Palva, Proc. Natl. Acad. Sci. 79:5582(1982) and EP Patent Pub. No. 244 042).

Transcription termination sequences recognized by bacteria are regulatory regions located 3' to the translation stop codon. Together with the promoter they flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the MCP-1R polypeptide encoded by the MCP-1R DNA sequence (SEQ ID NOS:1 and 3). Transcription termination sequences frequently include DNA sequences of about 50 nucleotides capable of forming stem loop structures that aid in terminating transcription. Examples include transcription termination sequences derived from genes with strong promoters, such as the trp gene in E. coli as well as other biosynthetic genes.

Typically, the promoter, signal sequence (if desired), coding sequence of interest, and transcription termination sequence are maintained in an extrachromosomal element (e.g., a plasmid) capable of stable maintenance in the bacterial host. The plasmid will have a replication system, thus allowing it to be maintained in the bacterial host either for expression or for cloning and amplification. In addition, the plasmid can be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging

24.

from about 5 to about 200, and typically about 10 to about 150. A host containing a high copy number plasmid will preferably contain at least about 10, and more preferably at least about 20 plasmids.

Alternatively, the expression constructs can be integrated into the bacterial  
5 genome with an integrating vector. Integrating vectors typically contain at least one sequence homologous to the bacterial chromosome that allows the vector to integrate. Integrations appear to result from recombinations between homologous DNA in the vector and the bacterial chromosome. See e.g., EP Patent Pub. No. 127 328.

10 Typically, extrachromosomal and integrating expression constructs can contain selectable markers to allow for the selection of bacterial strains that have been transformed. Selectable markers can be expressed in the bacterial host and can include genes which render bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin (neomycin), and tetracycline (see  
15 Davies, Ann. Rev. Microbiol. 32:469(1978). Selectable markers can also include biosynthetic genes, such as those in the histidine, tryptophan, and leucine biosynthetic pathways.

Alternatively, some of the above described components can be put together in transformation vectors. Transformation vectors are typically comprised of a  
20 selectable marker that is either maintained in an extrachromosomal vector or an integrating vector, as described above.

Expression and transformation vectors, either extra-chromosomal or integrating, have been developed for transformation into many bacteria. Exemplary are the expression vectors disclosed in Palva, Proc. Natl. Acad. Sci. 79:5582(1982), EP  
25 Patent Pub. Nos. 036 259 and 063 953 and PCT Patent Publication WO 84/04541 (for *B. subtilis*); in Shimatake, Nature 292:128(1981), Amann, Gene 40:183(1985), Studier, J. Mol. Biol. 189:113(1986) and EP Patent Pub. Nos. 036 776, 136 829 and 136 907 (for *E. coli*); in Powell, Appl. Environ. Microbiol. 54:655(1988) and U.S. Patent No. 4,745,056 (for *Streptococcus*).

30 Methods of introducing exogenous DNA into bacterial hosts are well-known in the art, and typically include either the transformation of bacteria treated with

25.

- CaCl<sub>2</sub> or other agents, such as divalent cations and DMSO. DNA can also be introduced into bacterial cells by electroporation. Exemplary methodologies can be found in Masson, FEMS Microbiol. Let. 60:273(1989), Palva, Proc. Natl. Acad. Sci. 79:5582(1982), EP Patent Pub. Nos. 036 259 and 063 953 and PCT
- 5 Patent Pub. WO 84/04541 for Bacillus transformation. For campylobacter transformation, see e.g., Miller, Proc. Natl. Acad. Sci. 85:856(1988) and Wang, J. Bacteriol. 172:949(1990). For E.coli, see e.g., Cohen, Proc. Natl. Acad. Sci. 69:2110(1973), Dower, Nuc. Acids Res. 16:6127(1988), Kushner, Genetic Engineering: Proceedings of the International Symposium on Genetic Engineering
- 10 (eds. H.W. Boyer and S. Nicosia), Mandel, J. Mol. Biol. 53:159(1970) and Taketo, Biochem. Biophys. Acta 949:318(1988). For Lactobacillus and Pseudomonas, see e.g., Chassy, FEMS Microbiol. Let. 44:173(1987) and Fiedler, Anal. Biochem. 170:38(1988), respectively. For Streptococcus, see e.g., Augustin, FEMS Microb. Let. 66:203(1990), Barany, J. Bacteriol.
- 15 144:698(1980), Harlander, Streptococcal Genetics (ed. J. Ferretti and R. Curtiss III)(1987), Perry, Infec. Immun. 32:1295(1981), Powell, Appl. Environ. Microbiol. 54:655(1988) and Somkuti, Proc. 4th Evr. Cong. Biotechnology 1:412(1987).

### 20 III. Expression and Detection of Expressed MCP-1R Proteins

In order to obtain MCP-1R expression, recombinant host cells derived from the transformants are incubated under conditions which allow expression of the MCP-1R encoding sequence (SEQ ID NOS:1 AND 3). These conditions will vary, depending upon the host cell selected. However, the conditions are readily

25 ascertainable to those of ordinary skill in the art, based upon what is known in the art.

Detection of an MCP-1R protein expressed in the transformed host cell can be accomplished by several methods. For example, detection can be by enzymatic activity (or increased enzymatic activity or increased longevity of enzymatic

30 activity) using fluorogenic substrates which are comprised of a dibasic cleavage site

26.

for which an MCP-1R protein is specific. An MCP-1R protein can also be detected by its immunological reactivity with anti-MCP-1R antibodies.

#### IV. Identification of MCP-1 Receptor Antagonists

5 Different ligands of a cellular receptor are classified on the basis of their capacity to induce biological responses. Substances that are both capable of binding to the receptor and triggering a response are classified as agonists. By contrast, ligands that are capable of binding to the receptor but are incapable of triggering a response are classified as antagonists. Antagonists compete, sometimes  
10 extremely effectively, with the natural ligand or its agonists, leading to functional receptor inactivation (receptor antagonism).

A method is provided for identifying ligands of the MCP-1 receptor, such as antagonists. The method comprises transfecting a mammalian cell line with an expression vector comprising nucleic acid sequences encoding the N-terminal  
15 domain of MCP-1 receptor (see SEQ ID NOS:1 and 3). The N-terminal domain of the MCP-1 receptor may be expressed alone or in combination with other domains of the MCP-1 receptor. The other domains may be extracellular, intracellular or transmembrane domains. Moreover, a chimaeric protein may be expressed, where the other domains are the corresponding domains from related  
20 proteins, such as those in Fig. 4 (SEQ ID NOS:5, 6, 7 and 8). The N-terminal domain may also be expressed as a portion of the native MCP-1 receptor. Expression of extracellular domains is preferred where soluble protein for solid phase assays is required.

The antagonist is identified by adding an effective amount of an organic  
25 compound to the culture medium used to propagate the cells expressing the N-terminal domain of MCP-1 receptor. An effective amount is a concentration sufficient to block the binding of MCP-1 to the receptor domain. The loss in binding of MCP-1 to the receptor may be assayed using various techniques, using intact cells or in solid-phase assays.

30 For example, binding assays similar to those described for IL-7 in U.S. Patent No. 5,194,375 may be used. This type of assay would involve labelling MCP-1

27.

and quantifying the amount of label bound by MCP-1 receptors in the presence and absence of the compound being tested. The label used may, for example, be a radiolabel, e.g.  $^{125}\text{I}$  or a fluorogenic label.

Alternatively, an immunoassay may be employed to detect MCP-1 binding to its  
5 receptor by detecting the immunological reactivity of MCP-1 with anti-MCP-1  
antibodies in the presence and absence of the compound being tested. The  
immunoassay may, for example, involve an antibody sandwich assay or an  
enzyme-linked immunoassay. Such methods are well known in the art and are  
described in Methods in Enzymology, Volumes 154 and 155 (Wu and Grossman,  
10 and Wu, Eds., respectively), (Mayer and Walker, Eds.) (1987); Immunochemical  
Methods in Cell and Molecular Biology (Academic Press, London).

Pharmaceutical compositions comprising the MCP-1 receptor antagonist may be  
used for the treatment of disease characterized by monocytic infiltrates, such as  
rheumatoid arthritis and alveolitis. The antagonist is administered as a  
15 pharmaceutical composition comprising a therapeutically effective amount of the  
antagonist and a pharmaceutically acceptable vehicle. Such pharmaceutical  
compositions may also contain pharmaceutically acceptable carriers, diluents,  
fillers, salts, buffers, stabilizers and/or other materials well-known in the art. The  
term "pharmaceutically acceptable" means a material that does not interfere with  
20 the effectiveness of the biological activity of the active ingredient(s) and that is not  
toxic to the host to which it is administered. The characteristics of the carrier or  
other material will depend on the route of administration.

Administration can be carried out in a variety of conventional ways. Parenteral  
administration is currently preferred. In such cases, the antagonist composition  
25 may be in the form of a non-pyrogenic, sterile, parenterally acceptable aqueous  
solution. The preparation of such parenterally acceptable solutions, having due  
regard to pH, isotonicity, stability and the like, is within the skill in the art. In the  
long term, however, oral administration will be advantageous, since it is expected  
that the active antagonist compositions will be used over a long time period to treat  
30 chronic conditions.

28.

The amount of active ingredient will depend upon the severity of the condition, the route of administration, the activity of the antagonist, and ultimately will be decided by the attending physician. It is currently contemplated, however, that the various pharmaceutical compositions should contain about 10 micrograms to about  
5 1 milligram per milliliter of antagonist.

In practicing the method of treatment of this invention, a therapeutically effective amount of the antagonist composition is administered to a human patient in need of such treatment as a result of having a condition characterized by monocytic infiltrates. The term "therapeutically effective amount" means the total amount of  
10 the active component of the method or composition that is sufficient to show a meaningful patient benefit, i.e., healing of chronic conditions or increase in rate of healing. A therapeutically effective dose of an antagonist composition of this invention is contemplated to be in the range of about 10 micrograms to about 1 milligram per milliliter per dose administered. The number of doses administered  
15 may vary, depending on the individual patient and the severity of the condition.

The invention is further described in the following examples, which are intended to illustrate the invention without limiting its scope.

#### V. Examples

20 Standard procedures for the isolation and manipulation of DNA are from Sambrook, *et al.* (1989). Plasmid DNA was propagated in *E. coli* strains HB101, D1210 or XL-1 Blue (Stratagene). DNA sequencing was performed by the dideoxy chain termination method (Sanger, 1977) using M13 primers as well as specific internal primers.

25

##### Example 1

##### PCR Identification of cDNA Clones

To identify and clone new members of the chemokine receptor gene family, degenerate oligonucleotide primers were designed and synthesized corresponding  
30 to the conserved sequences NLAISDL (SEQ ID NO: 11) in the second and DRYLAIV (SEQ ID NO:12) in the third transmembrane domains of the MIP-

29.

1 $\alpha$ /RANTES receptor, the IL-8 receptors and the HUMSTR orphan receptor (GenBank Accession #M99293). Amplification of cDNA derived from MM6 cells with the primers yielded a number of PCR products corresponding in size to those expected for a seven transmembrane receptor. Analysis of the subcloned PCR products revealed cDNAs encoding the predicted fragments of the receptors from which the primers were designed as well as one cDNA that appeared to encode a novel protein. To obtain a full-length version of this clone, a MM6 cDNA library was constructed in pFROG and probed by hybridization with the PCR product. A 2.1kb cDNA clone was obtained. Analysis of additional clones in the MM6 cDNA library revealed a second sequence that was identical to the 2.1kb cDNA sequence first obtained from the 5' untranslated region through the putative seventh transmembrane domain but contained a different cytoplasmic tail from the 2.1kb cDNA sequence first obtained. Two independent clones in the library were found to contain the second sequence, which appears to represent alternative splicing of the carboxyl-terminal tail of the MCP-1R protein. The two sequences are denoted MCP-1RA and MCP-1RB, monocyte chemoattractant protein-1 receptors A and B, representing, respectively, the first and second sequences isolated (SEQ ID NOS:1, 2, 3 and 4). Details of the materials and methods used follow.

#### 20 1. Oligonucleotide Synthesis

Oligonucleotide adapters, probes, and primers were synthesized on an Applied Biosystems (Foster City, CA) instrument according to the manufacturer's instructions. The degenerate oligonucleotide primers corresponding to conserved sequences in the second and third transmembrane domains as noted above and incorporating EcoRI and XhoI restriction sites in their 5' ends that were used to identify MCP-1R were a 27-mer, 5' CGC TCG AGA CCT (G or A)(G or T)C (C or A)(A, T or G)T (T or G)(T or G)C (T or C)GA CCT 3' (SEQ ID NO:9) and a 31-mer 5' GC GAA TTC TGG AC(G or A) ATG GCC AGG TA(C,A or G) C(T or G)G TC 3' (SEQ ID NO:10).

30

30.

## 2. Polymerase Chain Reactions (PCR)

MM6 cells, which are derived from a human monocytic leukemia (see Weber, Eur. J. Immunol. 23:852-59(1993)) were obtained from the DSM German Collection of Microorganisms and Cell Cultures, Masheroder Weglb, 3300  
5 Braunschweig, Germany. The cells were grown in RPMI-1640 (GIBCO BRL, Grand Island, N.Y.), supplemented with 10% fetal calf serum, 25mM Hepes, and antibiotics. Total RNA was isolated from the MM6 cells by the method of Chomczynski and Sacchi. See Chomczynski, Anal. Biochem. 162:156-59(1987). Poly A<sup>+</sup> RNA was obtained by affinity chromatography on oligo dT cellulose  
10 columns (Pharmacia, Piscataway, N.J.). First strand cDNA synthesis was performed starting with 5 $\mu$ g of MM6 poly A<sup>+</sup> RNA according to the manufacturer's instructions (Pharmacia).

PCR reactions were carried out for 30 cycles beginning with a 1-minute incubation at 94°C, 2 minutes at 50°C, 1.5 minutes at 72°C, and a final elongation  
15 step at 72°C for 4 minutes using the PCR primers described above (SEQ ID NOS:9 and 10) at a final concentration of 1  $\mu$ M and MM6 cDNA at approximately 10 ng/ml. PCR products migrating between 200 -300 base pairs on a 1.5% agarose gel were excised, subcloned into pBluescript (sk') and sequenced using fluorescently labeled dideoxyribonucleotides as described by Sanger, Proc Natl  
20 Acad SciUSA 74:5463-67(1977). Sequence analysis revealed cDNAs encoding the predicted fragments of the receptors upon which the primers were designed and one cDNA which appeared to encode a novel protein. To obtain a full-length version of this clone, an appropriate cell line was chosen and a cDNA library was constructed in pFROG and probed with this PCR product, as detailed in  
25 subsections 3 and 4 below.

## 3. Identification of the MM6 Cell Line

Because monocytes are difficult to isolate in usable quantity and express less than 2000 high affinity MCP-1 binding sites per cell, a cultured cell line that  
30 responded well to MCP-1 had to be identified. Using the calcium efflux assay as described in Vu, Cell 64:1057-68(1991), MCP-1 induced calcium fluxes in various



31.

cell lines were measured. No calcium flux was detected in undifferentiated human HL-60 cells and human erythroleukemia (HEL) cells. In contrast, a dose-dependent calcium flux was detected in MM6 cells, with half maximal stimulation at 4nM MCP-1. The response of MM6 cells to MCP-1 could not be ablated by  
5 prior exposure to RANTES, whereas the response to RANTES was partially blocked by prior exposure to MCP-1. Similar results obtained when MIP-1 $\alpha$  was used instead of RANTES.

#### 4. Expression Cloning of MCP-1 Receptor

10 The overall strategy for cloning the MCP-1 receptor was to confer MCP-1 responsiveness to *Xenopus* oocytes that were microinjected with RNA encoding the receptor. This methodology has been successfully employed to clone the 5-HT, thrombin, IL8RA, and MIP-1 $\alpha$ /RANTES receptors. Oocytes are harvested from gravid frogs, and treated with collagenase to remove the follicular cells. The  
15 cDNA library is electroporated into bacterial host cells which are then divided into pools of 5,000 to 50,000 colonies/petri dish. DNA is prepared from each pool of bacteria and linearized. One day after harvesting, the oocytes are microinjected with poly A + RNA or cRNA transcribed from the linearized cDNAs and incubated for two days to allow protein expression. On the day of the experiment, the  
20 oocytes are loaded with <sup>45</sup>Ca, washed to remove unincorporated <sup>45</sup>Ca, and then incubated with potential ligands. In the presence of the appropriate ligand a significant afflux of <sup>45</sup>Ca is detected. Uninjected oocytes are used as controls. A minimum of 1,000,000 colonies are screened (i.e., 20 to 200 pools) and if a positive pool is found it is subdivided (sibed) into smaller pools which are then  
25 individually screened. The process is repeated until a single clone is obtained.

As a prelude to undertaking this very labor intensive approach, poly A + RNA from large scale preparations of THP-1 and MM6 cells was injected into oocytes, but failed to confer MCP-1 dependent signaling. Furthermore, larger mRNA species were enriched by size fractionation of 200-300 $\mu$ g of poly A + THP-1 and  
30 MM6 RNA on sucrose gradients before injecting individual fractions into oocytes. Once again MCP-1 dependent signaling in oocytes was not demonstrated. In

32.

addition, injection of a limited number of cRNAs transcribed from library pools also failed to confer signaling. These experiments suggested that the MCP-1 receptor message is most likely of low abundance, and not detectable in a pool size large enough to make expression cloning by sib-selection feasible. For this reason,  
5 the polymerase chain reaction (PCR)-based strategy was pursued.

#### 5. Construction and Screening of the MM6 cDNA Library

A cDNA library was constructed in the vector pFROG, a modified version of pCDM6 that includes approximately 100 bases of 5' untranslated xenopus globin  
10 sequence just 3' of the SP6 promoter, as described by Vu, Cell 64:1057-68 (1991).

After first strand and second strand synthesis from MM6 poly A<sup>+</sup> RNA was performed (see subsection 2 above), the cDNA was size selected for 2kb or greater by agarose gel electrophoresis. BstXI linkers were added for insertion into the  
15 pFROG vector. After ligation, pFROG was electroporated into competent MC1061p3 cells. A total of 1,000,000 colonies were screened by hybridization under conditions of high stringency (50% formamide, 6x SSC, 0.1% SDS, 42°C, 16h) as described in Sambrook, Molecular Cloning: A Laboratory Manual, Second Edition (1989) using the novel PCR product isolated as described in subsection 2  
20 above. Positives were sequenced using fluorescently labeled dideoxyribonucleotides as described by Sanger, Proc. Natl. Acad. Sci. 74:5463 (1977). Two cDNA clones containing the A form of the receptor and two clones containing the B form were isolated.

25

#### Example 2

##### Structure of MCP-1R Deduced from the cDNA Sequence

The full sequence of MCP-1RA cDNA (SEQ ID NO:1) and the encoded amino acid sequence (SEQ ID NO:2) are shown in FIG. 1. The encoded protein sequence is shown below that of the cDNA sequence. The cDNA sequence (SEQ  
30 ID NO:3) and encoded amino acid sequence (SEQ ID NO:4) of MCP-1RB are shown in Figure 2. Conventional numbering is used.

## 33.

The translation of both MCP-1R DNAs is most likely initiated at the ATG start codon. This is the only in-frame MET codon in the 5' region of the cDNA. Following the initiating methionine (MET) is an open reading frame encoding a protein of 374 amino acids with a predicted molecular weight of about 42,000  
5 Daltons. By direct comparison with the known transmembrane domains for the MIP-1 $\alpha$ /RANTES receptor, the orphan receptor HUMSTSR and the IL-8 receptors 8RA and 8RB, an extra cellular amino terminus of 48 residues is revealed. The transmembrane domains are most likely located at amino acids 49 through 70, 80 through 700, 115 through 136, 154 through 178, 204 through 231, 244 through  
10 268 and 295 through 313. They are indicated in FIG. 4 by the horizontal lines above the sequence groupings (SEQ ID NOS: 2, 5, 6, 7 and 8). The carboxyl tail of 61 amino acids begins with serine at position 314 (see FIG. 4).

The MCP-1RB cDNA encodes an amino acid sequence identical to that of MCP-1RA from the MET at position 1 through the arginine at position 313 and including  
15 30 untranslated nucleotides immediately 5' of the initiating MET (see FIG. 2). The putative amino acid sequence of MCP-1RB (SEQ ID NO:4) however reveals a completely different cytoplasmic tail than the 61 amino acid cytoplasmic tail of MCP-1RA (SEQ ID NO:2). MCP-1RB has a cytoplasmic tail of 47 amino acids beginning with arginine at amino acid position 314 and ending with leucine at  
20 position 360. That alternative splicing occurred at position 313 can be inferred from the sequence identity, including the 5' untranslated sequence, of the two clones and from the characteristic AG sequence located at the putative donor junction between amino acid positions 313-314. In addition, a cDNA common to both A and B forms of MCP-1R hybridized to a single band on Southern blots of  
25 human genomic DNA under high stringency conditions, and one cDNA clone from the MM6 library was obtained that contained in tandem both carboxyl-terminal cytoplasmic tails found in MCP-1RA and 1RB, suggesting derivation from incompletely processed RNA. The MCP-1 receptor, MCP-1R, is only the second known example of alternative splicing of the carboxyl tails of receptors in the  
30 seven-transmembrane receptor family. Namba, Nature 365:166-70(1993) has reported that the prostaglandin (PG) E2 receptor has four alternatively spliced

34.

carboxyl-terminal tails with little sequence homology among the four. The related MIP-1 $\alpha$ /RANTES and IL-8 receptors are believed to be intronless. See Holmes, Science 253:1278-80(1991); Murphy, Science 253:1280-83(1991) and Neote, Cell 72:415-25(1993). Alignment of the cytoplasmic tails of MCP-1RA and 1RB with  
5 other chemokine receptors revealed that one of the receptors, MCP-1RB, was homologous to the corresponding region in the MIP-1 $\alpha$ /RANTES receptor. The carboxyl tail of MCP-1RA bore no significant identity with other known proteins.

Northern blots of hematopoietic cell lines were performed as described in Sambrook, Molecular Cloning: A Laboratory Manual, Second Edition (1989), and  
10 probed for each of the MCP-1R clones revealed that both mRNA species migrated as a single 3.5kb band. See FIG. 3. Both mRNAs were expressed at approximately equal levels in the MCP-1 responsive cell lines MM6 and in THP-1 cells. Neither were expressed in the unresponsive cell lines HEL and HL-60. Expression of each of the mRNA was also detected in freshly isolated human  
15 monocytes by reverse transcription PCR.

### Example 3

#### Similarity of MCP-1RA and 1RB to Other Seven

##### Member Transmembrane Receptors

20 Comparison of the sequences of MCP-1RA (SEQ ID NO:2) with the IL-8 receptors RA and RB, the MIP-1 $\alpha$ /RANTES receptor and the orphan receptor HUMSTR (SEQ ID NOS:7, 8, 5 and 6, respectively) is illustrated in FIG. 4. Comparison of the deduced amino acid sequence of the novel MCP-1A receptor with other seven transmembrane proteins revealed that it most closely relates to the  
25 MIP-1 $\alpha$ /RANTES receptor, with 51% identity at the amino acid level. The IL-8 receptors RA and RB exhibited 30% identity at the amino acid level to and the HUMSTR orphan receptor exhibited 31% identity at the amino acid level. Analysis reveals that the MCP-1 receptor has diverged from the related MIP-1 $\alpha$ /RANTES receptor and the IL-8 receptors in its amino-terminal and carboxyl-  
30 terminal domains. A striking identity between the MCP-1A receptor and the MIP-1 $\alpha$ /RANTES receptor is found in the sequence IFFIILLTI DRYLAIV

35.

HAVFAL(K/R) ARTVTFGV (SEQ ID NOS: 13 and 14), which occurs at the end of the third transmembrane domain (see FIG. 4). The corresponding region of rhodopsin is known to participate in G-protein binding (Franke et al.; Science 250:123 (1990)), suggesting that this domain may mediate aspects of G-protein activation common to receptors for C-C chemokines.

#### Example 4

##### Confirmation of Receptor Activity

The calcium efflux assay was performed to confirm expression of functional MCP-1R protein and to determine whether the MCP-1 receptors A and B conferred responsiveness to MCP-1 or other chemokines. In this assay, MCP-1RA and 1RB cRNA was microinjected into *Xenopus* oocytes and receptor signaling activities measured by detection of agonist-induced calcium mobilization. Signaling activity by the MIP-1 $\alpha$ /RANTES receptor and the IL-8 receptor RA was examined in parallel.

As described in Vu, Cell 64:1057-68(1991), cRNA was prepared by SP6 RNA polymerase transcription from a NotI linearized vector and run on an agarose gel to confirm a single band of the expected size. One day after harvesting, oocytes were injected with 20 ng of cRNA in a total volume of 50 nl per oocyte. After incubation in modified Barth's buffer for 2 days at 16°C, the oocytes were loaded with Ca<sup>45</sup> (50 uCi/ml, Amersham, Arlington Heights, Virginia) for 3 hours, washed for one hour, and placed into wells of a 24-well dish in groups of seven, in a volume of 0.5 ml Ca<sup>45</sup> efflux was determined by collecting the media at 10 minute intervals and counting beta emissions in a liquid scintillation counter. After a stable baseline had been achieved, cytokine agonists MIP-1 $\alpha$ , MIP-1 $\beta$ , RANTES, IL-8 and MCP-1 were added in the Barth's media to the oocytes for 10 minutes. Uninjected oocytes were used as controls. The cytokines, MIP-1 $\alpha$ , MIP-1 $\beta$ , RANTES, IL-8 and MCP-1 were obtained from R&D Inc., Minneapolis, Minnesota. The results are shown in FIG. 6.

Both MCP-1RA and 1RB conferred robust and remarkably specific responses to nanomolar concentrations of MCP-1. No response was elicited by the chemokines

36.

MIP-1 $\alpha$ , MIP-1 $\beta$ , RANTES, or IL-8, even when these ligands were present at 500nM. In contrast, the MIP-1 $\alpha$ /RANTES receptor signaled in response to MIP-1 $\alpha$  and RANTES, but not to MCP-1, consistent with published results. The EC<sub>50</sub> for MCP-1 was 15 nM.

5

### Example 5

#### MCP-1R Ligand Specificity and Signal Transduction

##### A. Ligand Specificity

A cell line stably expressing an MCP-1R receptor was produced by transfection  
10 of MCP-1RB cDNA into HEK-293 cells.

Human embryo kidney (HEK)-293 (CRL 1573) cells were obtained from the American Type Culture Collection (Bethesda, MD) and were grown in Minimal Essential Media with Earle's Balanced Salt Solution (MEM-EBSS; GIBCO/BRL, Grand Island, N.Y.) supplemented with 10% fetal calf serum ("FCS") (Hyclone  
15 Laboratories Inc., Logan, UT) and 1% penicillin/streptomycin, at 37°C in a humidified 5% CO<sub>2</sub> atmosphere. cDNAs for the MCP-1 receptor, MCP-1RB, and the MIP-1 $\alpha$ /RANTES receptor were cloned into the polylinker of the mammalian cell expression vector pcDNA3 (Invitrogen Inc., San Diego, CA) and transfected into 293 cells (50-80% confluent) with a DNA/Lipofectamine (GIBCO/BRL)  
20 mixture according to the manufacturer's instructions. After selection for 2-3 weeks in the presence of G418 (0.8 mg/ml) (GIBCO/BRL), colonies were picked and stable cell lines were screened by northern blot analysis for receptor expression. In general, there was a strong correlation between the level of receptor expression as judged by northern blot analysis and the strength of the receptor signals obtained  
25 in the below described functional assays. Transfected cells that failed to express the receptor on northern blots were used as negative controls in the binding and signaling experiments.

Equilibrium binding assays were then performed using the method of Ernst, J. Immunol. 152: 3541-49 (1994). Varying amounts of <sup>125</sup>I-labeled MCP-1 (Dupont-  
30 NEN, Boston, MA) were incubated with 6 x 10<sup>6</sup> MCP-1RB expressing HEK-293 cells resuspended in binding buffer (50 mM Hepes, pH 7.2, 1 mM CaCl<sub>2</sub>, 5 mM

37.

MgCl<sub>2</sub>, 0.5% BSA (bovine serum albumin, fraction V, Sigma)) in the presence or absence of 100-fold excess of the unlabeled C-C chemokines MIP-1 $\alpha$ , MIP-1 $\beta$  and RANTES, and the C-X-C chemokine IL-8 (chemokines obtained from R&D Systems, Inc., Minneapolis, MN). Competition experiments were performed using  
5 500 pM <sup>125</sup>I-labeled MCP-1 and the concentrations of unlabeled chemokines as indicated in Fig. 7.

Equilibrium binding data were analyzed according to the method of Scatchard using the program "LIGAND" (Biosoft, Ferguson, MO) on a Macintosh computer. See Munson, Anal. Biochem. 107: 220-39 (1980). The closely related C-C  
10 chemokines MIP-1 $\alpha$ , MIP-1 $\beta$ , and RANTES, as well as the C-X-C chemokine IL-8 did not compete for binding. Nor was specific binding detected in transfectants that expressed little or no MCP-1RB on Northern blots. Analysis of equilibrium binding data shown in Fig. 7 indicates a dissociation constant ( $K_d$ ) of 260 pM (Fig. 7B). This  $K_d$  is in good agreement with that reported for the binding of  
15 MCP-1 to monocytes (Yoshimura, J. Immunol. 145:292-97 (1990); Zhang, J. Biol. Chem. 269:15918-24 (1994)) and THP-1 cells (Van Riper, J. Exp. Med. 177:851-56 (1933)). These data indicate that <sup>125</sup>I-MCP-1 bound specifically and with high affinity to the MCP-1RB receptor expressed in 293 cells.

## 20 B. Signal Transduction

Calcium mobilization in 293 cells was then investigated. Transfected HEK-293 cells were grown until confluent, trypsinized briefly, washed with phosphate buffered saline containing 1 mg/ml BSA (PBS-BSA), and resuspended in serum-free MEM-EBSS supplemented with 1 mg/ml BSA and 10 mM HEPES (pH 7.0)  
25 at a density of 2 x 10<sup>7</sup> cells/ml. The cells were incubated in the dark at 37°C for 20 min in the presence of 5-10  $\mu$ g/ml indo-1 AM (Molecular Probes, Inc., Eugene, OR). Nine volumes of PGS-BSA were added, and the cells were incubated for an additional 10 min at 37°C, pelleted by centrifugation, and washed twice with 50 ml of the PBS-BSA solution. Washed, indo-1-loaded cells were then resuspended  
30 in Hank's Balanced Salt Solution (1.3 mM Ca<sup>2+</sup>) supplemented with 1 mg/ml BSA (HBS-BSA) at a density of approximately 0.5 x 10<sup>6</sup> cells/ml at room temperature.

38.

To measure intracellular calcium ( $[Ca^{2+}]_i$ ), 0.5 ml of the cell suspension was placed in a quartz cuvette in a Hitachi F-2000 fluorescence spectrophotometer. Chemokines (MCP-1, RANTES, MIP-1 $\alpha$ , MIP-1 $\beta$ , Gro- $\alpha$  and IL-8) dissolved in HBS-BSA were injected directly into the cuvette in 5  $\mu$ l volumes. Intracellular calcium was measured by excitation at 350 nm and fluorescence emission detection at 490 nm (F1) and 410 nm (F2) wavelengths. The  $[Ca^{2+}]_i$  was estimated by comparing the 490/410 fluorescence ratio after agonist application (R) to that of calibration ratios measured at the end of each run, according to the equation:

$$[Ca^{2+}]_i = K_d \times [(R - R_{min}) / (R_{max} - R)] \times (Sf2/Sb2)$$

where  $R_{max}$  and  $R_{min}$  represent the fluorescence ratio under saturating (1.3 mM  $Ca^{2+}$ ) and nominally free (10 mM EGTA, Sigma Chemical Co.) calcium conditions,  $K_d$  is the dissociation constant of calcium for indo-1, R is the fluorescence ratio, and Sf2/Sb2 is the fluorescence ratio of free and bound indo-1 dye at 410 nm. See Thomas, AP and Delaville, F (1991) in Cellular Calcium, a Practical Approach, Oxford Univ. Press, pp. 1-54.

To quantitate calcium responses, MCP-1 dose response curves were generated in each experiment and the results were expressed as a percent of the maximum calcium signal (at 300 nM MCP-1) measured in that experiment. The changes in  $[Ca^{2+}]_i$  levels in response to each concentration of agonist were determined by subtracting the baseline from peak  $[Ca^{2+}]_i$  levels, which were determined by averaging 5 seconds of data prior to agonist addition and surrounding the peak response, respectively. In experiments done to determine the role of extracellular calcium, 3 mM EGTA was added 60-90 seconds prior to MCP-1. Subsequent lysis of the cells with Triton X-100 (Sigma) caused no change in indo-1 fluorescence, indicating that EGTA had reduced the extracellular calcium concentration below that of intracellular basal levels (approximately 70-100 nM). All experiments were performed at room temperature.

MCP-1 stimulated robust calcium mobilization in the stably transfected MCP-1RB/293 cells in a specific and dose-dependent manner. Small but reproducible signals were seen with as little as 100 pM MCP-1, and the average  $EC_{50}$  from four full dose-response curves to MCP-1 was 3.4 nM (2.7-4.4 nM; Fig. 8, A and B).



39.

The MCP-1RB receptor was selectively activated by MCP-1. RANTES, MIP-1 $\alpha$ , MIP-1 $\beta$ , Gro- $\alpha$ , and IL-8 failed to stimulate significant calcium signals in these same cells, even when present at high concentrations (Fig. 8B). Furthermore, these chemokines also failed to block stimulation of the cells by MCP-1, indicating that they are unlikely to act as endogenous antagonists of the MCP-1RB receptor. The MCP-1-dependent intracellular calcium fluxes were characterized by short lag times, followed by a rapid rise in  $[Ca^{2+}]_i$  that returned to near basal levels within 80-90 sec of the addition of MCP-1 (Fig. 8A). The cells demonstrated homologous desensitization in that they were refractory to activation by a second challenge with MCP-1 (Fig. 8C).

To determine the source of the intracellular calcium flux, the MCP-1RB/293 cells were challenged with MCP-1 in the presence or absence of extracellular calcium. The rise in cytoplasmic calcium was largely unchanged by the chelation of extracellular calcium with 3 mM EGTA. Similar results were seen when the cells were washed and resuspended in calcium-free PBS supplemented with 1 mM EGTA, or when 5 mM  $Ni^{2+}$  was added to the cuvette to block the influx of extracellular calcium. Sozani, *J. Immunol.* 147:2215-21 (1991); Saga, *J. Biol. Chem.* 262:16364-69 (1987). The fall in cytoplasmic calcium to baseline was slightly prolonged in the presence of extracellular calcium, suggesting that calcium influx may contribute to maintaining the response to MCP-1 after intracellular stores are depleted. These data suggest that the primary means of calcium mobilization in these transfected 293 cells is through release of intracellular calcium.

Inositol (1,4,5)-triphosphate ( $IP_3$ ) mobilizes intracellular calcium in response to activation of a wide spectrum of receptors, including many seven-transmembrane-domain receptors. Hung, *J. Cell. Biol.* 116:827-32 (1992); Putney, *Trends Endocrinol. Metab.* 5:256-60 (1994). To investigate this mobilization, total inositol phosphate accumulation was determined as described in Hung, *J. Cell Biol.* 116: 827-32 (1992). HEK-293 cells were grown until confluent in 24-well tissue culture dishes and labeled overnight with 2  $\mu$ Ci/ml  $[^3H]$ myo-inositol (23 Ci/mmol) (New England Nuclear, Boston, MA) in inositol-free MEM-EBSS supplemented

40.

with 10% dialyzed FCS. Following labeling, the media were removed and the cells were incubated at room temperature for 5-10 min in 0.5 ml of serum-free MEM-EBSS media supplemented with 10mM HEPES, 1 mg/ml BSA, and 10 mM LiCl. The washed cells were then incubated with the chemokines MCP-1, MIP-1 $\alpha$ , MIP-1 $\beta$ , RANTES, IL-8 and Gro- $\alpha$  for 1-30 min at room temperature in the presence of 10 mM LiCl. The incubation was terminated by removal of the incubation media and addition of 1 ml of ice-cold 20 mM formic acid. Plates were incubated at 4°C for 30 min before the supernatants were applied to 1-ml Dowex AG1-X8 (100-200 mesh, formate form, from Sigma) chromatography columns. Columns were washed with 8 ml of water followed by 5 ml of 40 mM sodium formate. Total [<sup>3</sup>H]inositol phosphates were eluted with 5 ml of 2 M ammonium formate/0.1 M formic acid and quantitated by liquid scintillation spectroscopy. Activation of the MCP-1 receptor in transfected 293 cells induced little or no hydrolysis of phosphatidyl inositol. In control experiments activation of the muscarinic (Lameh, *J. Biol. Chem.* 267:13406-412 (1992)) or oxytocin receptor, Kimura, *Nature* 356:526-29 (1992), co-transfected into these same 293 cells, led to a 5- to 9-fold increase in PI turnover.

To investigate inhibition of adenylyl cyclase activity, HEK-293 cells stably-transfected with the MCP-1RB receptor and the MIP-1 $\alpha$ /RANTES receptor were grown until confluent in 24-well tissue culture dishes and labeled overnight with 2  $\mu$ Ci/ml of [<sup>3</sup>H]adenine (25-30 Ci/mmol) (New England Nuclear, Boston, MA) in MEM-EBSS supplemented with 10% FCS. The next day, the cells were washed by incubation at room temperature with 0.5 ml of serum-free MEM-EBSS media supplemented with 10 mM HEPES, 1 mg/ml BSA, and 1 mM IBMX (3-isobutyl-1-methylxanthine) for 5 min. After removal of the wash media the cells were stimulated by addition of fresh media containing either chemokine (MCP-1, MIP-1 $\alpha$ , MIP-1 $\beta$ , RANTES, IL-8 and Gro- $\alpha$ ) alone, forskolin alone (10 $\mu$ M, Sigma Chemical Co., St. Louis, MO), or chemokine plus forskolin, all in the presence of 1 mM IBMX, for 20 min at room temperature. The incubation was terminated by replacement of the media with 1 ml of ice-cold 5% TCA (trichloroacetic acid), 1mM cAMP, and 1 mM ATP (Sigma). Following incubation at 4°C for 30 min,

41.

the labeled [ $^3\text{H}$ ]ATP and [ $^3\text{H}$ ]cAMP pools were separated and quantitated by chromatography on Dowex 50W (200-400 mesh, hydrogen form, from Sigma) and neutral alumina columns (also from Sigma), as described in Hung, J. Biol. Chem. 267: 20831-34 (1992) and Wong, Nature 351: 63-65 (1991). The 1 ml acid  
5 supernatant was loaded onto a 1-ml Dowex 50W column and the ATP pool eluted with 3 ml of  $\text{H}_2\text{O}$ . The Dowex 50W columns were then placed over 1-ml alumina columns, and 10 ml of  $\text{H}_2\text{O}$  was added to the Dowex resin and the eluant allowed to drop directly onto the neutral alumina. The cAMP pool was then eluted directly from the alumina with 5 ml of 0.1 M imidazole/0.01 mM sodium azide. The  
10 [ $^3\text{H}$ ]ATP and [ $^3\text{H}$ ]cAMP fractions were counted by liquid scintillation spectroscopy. The cAMP pool for each sample was normalized to its own ATP pool and expressed as a ratio by the equation (cAMP cpms/ATP cpms)  $\times$  100. In each experiment full dose-response curves were generated and expressed as a percent of the forskolin control.

15 Activation of the MCP-1 receptor resulted in a potent and dose-dependent inhibition of adenylyl cyclase activity. MCP-1 significantly reduced basal cAMP accumulation in these cells by 55% ( $p < 0.01$ , Student's  $t$  test). Forskolin activation of adenylyl cyclase increased cAMP levels 16-fold, and co-addition of MCP-1 blocked this increase by 78%, with an  $\text{IC}_{50}$  of 90 nM (70-140 pM). The  
20 magnitude and potency of MCP-1 inhibition of adenylyl cyclase activity was independent of the forskolin concentration (3-30  $\mu\text{M}$ ). MCP-1 neither stimulated nor inhibited cAMP formation in untransfected or pcDNA3 transfected 293 cell controls.

Together these results demonstrate that inhibition of adenylyl cyclase activity  
25 provides a sensitive and quantitative assay for MCP-1RB receptor activation in 293 cells. Virtually no activation of the MCP-1 receptor could be detected in this assay in response to high concentrations of RANTES, MIP-1 $\alpha$ , MIP-1 $\beta$ , IL-8, or Gro- $\alpha$  which is consistent with our observations in the calcium fluorimetric assay and in *Xenopus* oocytes (Example 5).

30 In similar experiments the MIP-1 $\alpha$ /RANTES receptor was stably transfected into 293 cells and also found to mediate potent and dose-dependent inhibition of

42.

adenylyl cyclase activity. Unlike the MCP-1RB receptor, however, the MIP-1 $\alpha$ /RANTES receptor was activated by multiple chemokines with varying degrees of potency. MIP-1 $\alpha$  and RANTES were virtually equipotent in inhibiting adenylyl cyclase activity with IC<sub>50</sub>s of 110 pM and 140 pM, respectively. MIP-1 $\beta$  (IC<sub>50</sub> = 820 nM) also inhibited adenylyl cyclase activity, though only at much higher concentrations, and neither blocked cAMP accumulation to the same extent as MIP-1 $\alpha$  and RANTES. The C-X-C chemokines IL-8 and Gro- $\alpha$  did not activate the MIP-1 $\alpha$ /RANTES receptor at up to 1 $\mu$ M.

Table I below compares the activation of the MCP-1 receptor and the MIP-1 $\alpha$ /RANTES receptor by a variety of chemokines and demonstrates the specificity of the MCP-1RB receptor for MCP-1, and the MIP-1 $\alpha$ /RANTES receptor for MIP-1 $\alpha$  and RANTES. Neither of the C-X-C chemokines was active on either of the two cloned C-C chemokine receptors.

TABLE I

*Specificity of the MCP-1 and MIP-1 $\alpha$ /RANTES Receptors*

<i>Inhibition of Adenylyl Cyclase</i>				
	<u>MCP-1RB</u>	<u>IC<sub>50</sub>(nM)</u>	<u>MIP-1<math>\alpha</math>/RANTES R</u>	<u>Selectivity</u>
MCP-1	.090		820	> 9000 for MCP-1R
MIP-1 $\alpha$	> 10 <sup>3</sup>		.110	> 9000 for MIP-1 $\alpha$ /RANTES R
RANTES	> 10 <sup>3</sup>		.140	> 7000 for MIP-1 $\alpha$ /RANTES R
MIP-1 $\beta$	> 10 <sup>3</sup>		10	> 100 for MIP-1 $\alpha$ /RANTES R
Gro- $\alpha$	> 10 <sup>3</sup>		> 10 <sup>3</sup>	
IL-8	> 10 <sup>3</sup>		> 10 <sup>3</sup>	

In all experiments, the maximum inhibition of adenylyl cyclase activity mediated by the MCP-1RB or MIP-1 $\alpha$ /RANTES receptor was ~80% and ~55%, respectively. Qualitatively similar signaling, manifested by the rapid rise in cytoplasmic calcium and potent inhibition of adenylyl cyclase, was observed in cells expressing the MCP-1RA receptor.

43.

### C. Inhibition of MCP-1R Activation

Inhibition of MCP-1RB receptor activation by bordetella pertussis toxin was investigated. Pertussis toxin (List Biological Labs, Inc., Campbell, CA) was dissolved in 0.01 M sodium phosphate, pH 7.0, 0.05 M sodium chloride and  
5 diluted into normal serum containing media at final concentrations of 0.1 ng/ml to 100ng/ml, and incubated with cells overnight (14-16 h) at 37°C. The conditions of the Pertussis toxin treatment of the 293 cells were identical for calcium fluorimetric and adenylyl cyclase experiments. In the adenylyl cyclase experiments, the Pertussis toxin was added at the same time as [<sup>3</sup>H]adenine.

- 10 The MCP-1-induced mobilization of intracellular calcium, as well as the inhibition of adenylyl cyclase, was substantially blocked by pretreatment of cells with bordetella pertussis toxin. Dose-response studies indicated a similar degree of inhibition of these two pathways by pertussis toxin, as well as a component (≈20%) that was resistant to inhibition by up to 100 ng/ml of PT. The effect of  
15 pertussis toxin treatment was to reduce the magnitude of the MCP-1 inhibition of cAMP accumulation without significantly shifting the MCP-1 IC<sub>50</sub>, a result consistent with the hypothesis that pertussis toxin treatment functionally uncouples the MCP-1RB receptor from G<sub>ai</sub>. These results also suggest that both the inhibition of adenylyl cyclase activity and the mobilization of intracellular calcium  
20 may be mediated through activation of the same G-protein in the 293 cells.

### D. Discussion of Results

- MCP-1 induced a rapid rise in intracellular calcium in indo-1-loaded 293 cells that were stably transfected with MCP-1RB. The stable cell line also demonstrated  
25 dose-dependent homologous desensitization of calcium mobilization in response to MCP-1. The relative contributions of extracellular and intracellular calcium stores to this calcium flux has been controversial. The results above support the conclusion that the initial rise in cytoplasmic calcium after activation of the MCP-1 receptor in 293 cells is almost exclusively due to the release of intracellular  
30 calcium stores. First, chelation of extracellular calcium with EGTA (2 mM to 10 mM) had little effect on the rise and peak levels of the calcium transients, but did

44.

hasten the return to baseline calcium levels. Second, the same result was obtained when the transfected cells were incubated in calcium-free media, supplemented with 1 mM EGTA. Finally, virtually identical results were obtained in the presence of 5 mM  $\text{Ni}^{2+}$ , which blocks the influx of extracellular calcium.

- 5     Activation of the MCP-1RB receptor led to profound inhibition of adenylyl cyclase, suggesting coupling via one of the isoforms of  $\text{G}\alpha\text{i}$ . Similar results were obtained using the cloned MIP-1 $\alpha$ /RANTES receptor, indicating that at least two of the receptors for C-C chemokines activate  $\text{G}\alpha\text{i}$ . Moreover, pertussis toxin blocked both the calcium mobilization as well as the inhibition of adenylyl cyclase
- 10    induced by MCP-1. Similarity in the pertussis toxin dose-response curves for calcium mobilization and inhibition of adenylyl cyclase suggests that both may be downstream consequences of coupling to  $\text{G}\alpha\text{i}$ . These studies are the first demonstration of adenylyl cyclase inhibition by chemokine receptors, and are consistent with reports that leukocyte chemotaxis to IL-8, fMLP and MCP-1 is
- 15    sensitive to inhibition by pertussis toxin. Oppenheim, Ann. Rev. Immunol. 9: 617-48 (1991); Spangrude, J. Immunol. 135: 4135-43 (1985); Sozzini, J. Immunol. 147: 2215-21 (1991).

Although inhibition of adenylyl cyclase is the most thoroughly characterized downstream effect of the activation of  $\text{G}\alpha\text{i}$  in leukocytes,  $\text{G}\alpha\text{i}$  has also been

20    implicated in the activation of potassium channels, in the induction of mitosis and in the activation of Ras and microtubule associated protein (MAP) kinase in fMLP stimulated neutrophils. Yatani, Nature 336:680-82 (1988); Seuwan, J. Biol. Chem. 265: 22292-99 (1990); Worthen, J. Clin. Invest. 94:815-23 (1994). Thus, activation of  $\text{G}\alpha\text{i}$  may activate a complex array of intracellular signals that

25    ultimately lead to leukocyte activation and chemotaxis.

A pertussis toxin-sensitive signal transduction pathway in which  $\beta\gamma$  dimers, released in conjunction with  $\text{G}\alpha\text{i}$ , activate the  $\beta_2$  isoform of the phospholipase C ( $\text{PLC}\beta_2$ ) to generate  $\text{IP}_3$  has been described. Wu, Science 261:101-031. Cellular activation via this pathway would be expected to result in a pertussis toxin-sensitive

30    mobilization of intracellular calcium. However, 293 cells stably expressing the recombinant MCP-1 receptor hydrolyze little, if any PI (phosphatidylinositol) when

45.

challenged with MCP-1. In control experiments, Gq-coupled receptors, co-transfected into this cell line, increased total inositol phosphates 5- to 9-fold upon activation. The failure to detect PI turnover in the MCP-1RB transfected cells suggests that the MCP-1 receptor mobilizes intracellular calcium via a novel  
5 mechanism independent of  $IP_3$ .

MCP-1RB was remarkably specific for MCP-1. In the cyclase assay the  $IC_{50}$  for inhibition by MCP-1 was 90 pM, whereas related chemokines were ineffective at up to 1  $\mu$ M. In contrast, the MCP-1- $\alpha$ /RANTES receptor has an  $IC_{50}$  of approximately 100 pM for MIP-1 $\alpha$  and RANTES, and 10 nM and 820 nM for  
10 MIP-1 $\beta$  and MCP-1, respectively. Thus, MCP-1 had a selectivity of at least 9000-fold for the MCP-1 receptor, whereas MIP-1 $\alpha$  and RANTES had a similar preference for the MCP-1- $\alpha$ /RANTES receptor, as compared to MCP-1RB. It is likely, therefore, that under physiological conditions, MCP-1, MIP-1 $\alpha$ , and RANTES act as specific agonists of MCP-1RB and the MCP-1- $\alpha$ /RANTES  
15 receptor, respectively.

The  $IC_{50}$  for MCP-1-mediated inhibition of adenylyl cyclase was approximately 90 pM, well below the dissociation constant for binding ( $K_d=260$  pM) which suggests that relatively few receptors must be occupied for efficient coupling to  $G_{\alpha i}$ . In contrast, very high receptor occupancy was required to elicit peak  
20 intracellular calcium fluxes ( $EC_{50}=2-4$  nM). It is interesting to note, in this regard, that the  $EC_{50}$  for monocyte chemotaxis to MCP-1 is subnanomolar. Yoshimura, J. Immunol. 145:292-97 (1990). Thus the induction of chemotaxis, which is the hallmark function of MCP-1 is optimal at MCP-1 concentrations that provide for efficient coupling/signaling through  $G_{\alpha i}$  but are insufficient to elicit  
25 maximal intracellular calcium fluxes and subsequent receptor desensitization, suggesting that modest increases in intracellular calcium are sufficient to initiate and support monocyte chemotaxis. The high levels of intracellular calcium detected at nanomolar concentrations of MCP-1 may serve to stop monocyte migration by desensitizing the receptor and unregulating adhesion molecules.

30 MCP-1 is synthesized and secreted *in vitro* by a number of different cells in response to a variety of different cytokines or oxidatively modified lipoproteins.

46.

The specificity of the cloned receptor for MCP-1, coupled with the fact that only monocytes, basophils, and a subset of T lymphocytes response to MCP-1, provides for an effective means of limiting the spectrum of infiltrating leukocytes in areas where MCP-1 is abundant. Early atherosclerotic lesions have a predominantly  
5 monocytic infiltrate and MCP-1 is abundant in these lesions. In contrast, the MCP-1- $\alpha$ /RANTES receptor binds and signals in response to multiple chemokines, and may serve to mediate more complex inflammatory reactions. Once activated, however, the MCP-1 and MCP-1- $\alpha$ /RANTES receptors appear to use similar signal transduction pathways.

- 10 Dose response curves generated in the calcium fluorimetric and adenylyl cyclase inhibition assays were fit by a nonlinear least squares program to the logistic equation:

$$\text{Effect} = \text{max effect} / [1 + (\text{EC}_{50} / (\text{agonist})^n)]$$

- 15 where  $n$  and  $\text{EC}_{50}$  represent the Hill coefficient and the agonist concentration that elicited a half-maximal response, respectively, and were derived from the fitted curve. Curve fitting was done with the computer program "Prism" (by Graph Pad, San Diego, CA). Results represent the mean  $\pm$  SE. The 95% confidence intervals (CI) of the  $\text{EC}_{50}$  and  $\text{IC}_{50}$  values, when given, were calculated from the log  $\text{EC}_{50}$   
20 and  $\text{IC}_{50}$  values, respectively.

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

- 25 The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.



47.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

5

(i) APPLICANT: The Regents of the University of California

(ii) TITLE OF INVENTION: MAMMALIAN MONOCYTE CHEMOATTRACTANT  
PROTEIN RECEPTORS

10

(iii) NUMBER OF SEQUENCES: 14

(iv) CORRESPONDENCE ADDRESS:

15

(A) ADDRESSEE: Robbins, Berliner &amp; Carson

(B) STREET: 201 N. Figueroa Street, 5th Floor

(C) CITY: Los Angeles

(D) STATE: California

(E) COUNTRY: USA

(F) ZIP: 90012-2628

20

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

25

(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

30

(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Berliner, Robert

(B) REGISTRATION NUMBER: 20,121

35

(C) REFERENCE/DOCKET NUMBER: 5555-291

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 310-977-1001

(B) TELEFAX: 310-977-1003

40

(C) TELEX:

48.

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 2232 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

10

## (iii) HYPOTHETICAL: NO

## (iv) ANTI-SENSE: NO

15

## (ix) FEATURE:

- (A) NAME/KEY: CDS  
 (B) LOCATION: 40..1161

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

20

GGATTGAACA AGGACGCATT TCCCCAGTAC ATCCACAAC ATG CTG TCC ACA TCT 54  
 Met Leu Ser Thr Ser  
 1 5

25 CGT TCT CGG TTT ATC AGA AAT ACC AAC GAG AGC GGT GAA GAA GTC ACC 102  
 Arg Ser Arg Phe Ile Arg Asn Thr Asn Glu Ser Gly Glu Glu Val Thr  
 10 15 20

30 ACC TTT TTT GAT TAT GAT TAC GGT GCT CCC TGT CAT AAA TTT GAC GTG 150  
 Thr Phe Phe Asp Tyr Asp Tyr Gly Ala Pro Cys His Lys Phe Asp Val  
 25 30 35

35 AAG CAA ATT GGG GCC CAA CTC CTG CCT CCG CTC TAC TCG CTG GTG TTC 198  
 Lys Gln Ile Gly Ala Gln Leu Leu Pro Pro Leu Tyr Ser Leu Val Phe  
 40 45 50

40 ATC TTT GGT TTT GTG GGC AAC ATG CTG GTC GTC CTC ATC TTA ATA AAC 246  
 Ile Phe Gly Phe Val Gly Asn Met Leu Val Val Leu Ile Leu Ile Asn  
 55 60 65

45 TGC AAA AAG CTG AAG TGC TTG ACT GAC ATT TAC CTG CTC AAC CTG GCC 294  
 Cys Lys Lys Leu Lys Cys Leu Thr Asp Ile Tyr Leu Leu Asn Leu Ala  
 70 75 80 85

45 ATC TCT GAT CTG CTT TTT CTT ATT ACT CTC CCA TTG TGG GCT CAC TCT 342  
 Ile Ser Asp Leu Leu Phe Leu Ile Thr Leu Pro Leu Trp Ala His Ser  
 90 95 100

49.

	GCT GCA AAT GAG TGG GTC TTT GGG AAT GCA ATG TGC AAA TTA TTC ACA Ala Ala Asn Glu Trp Val Phe Gly Asn Ala Met Cys Lys Leu Phe Thr 105 110 115	390
5	GGG CTG TAT CAC ATC GGT TAT TTT GGC GGA ATC TTC TTC ATC ATC CTC Gly Leu Tyr His Ile Gly Tyr Phe Gly Gly Ile Phe Phe Ile Ile Leu 120 125 130	438
10	CTG ACA ATC GAT AGA TAC CTG GCT ATT GTC CAT GCT GTG TTT GCT TTA Leu Thr Ile Asp Arg Tyr Leu Ala Ile Val His Ala Val Phe Ala Leu 135 140 145	486
15	AAA GCC AGG ACG GTC ACC TTT GGG GTG GTG ACA AGT GTG ATC ACC TGG Lys Ala Arg Thr Val Thr Phe Gly Val Val Thr Ser Val Ile Thr Trp 150 155 160 165	534
20	TTG GTG GCT GTG TTT GCT TCT GTC CCA GGA ATC ATC TTT ACT AAA TGC Leu Val Ala Val Phe Ala Ser Val Pro Gly Ile Ile Phe Thr Lys Cys 170 175 180	582
	CAG AAA GAA GAT TCT GTT TAT GTC TGT GGC CCT TAT TTT CCA CGA GGA Gln Lys Glu Asp Ser Val Tyr Val Cys Gly Pro Tyr Phe Pro Arg Gly 185 190 195	630
25	TGG AAT AAT TTC CAC ACA ATA ATG AGG AAC ATT TTG GGG CTG GTC CTG Trp Asn Asn Phe His Thr Ile Met Arg Asn Ile Leu Gly Leu Val Leu 200 205 210	678
30	CCG CTG CTC ATC ATG GTC ATC TGC TAC TCG GGA ATC CTG AAA ACC CTG Pro Leu Leu Ile Met Val Ile Cys Tyr Ser Gly Ile Leu Lys Thr Leu 215 220 225	726
35	CTT CGG TGT CGA AAC GAG AAG AAG AGG CAT AGG GCA GTG AGA GTC ATC Leu Arg Cys Arg Asn Glu Lys Lys Arg His Arg Ala Val Arg Val Ile 230 235 240 245	774
40	TTC ACC ATC ATG ATT GTT TAC TTT CTC TTC TGG ACT CCC TAT AAC ATT Phe Thr Ile Met Ile Val Tyr Phe Leu Phe Trp Thr Pro Tyr Asn Ile 250 255 260	822
	GTC ATT CTC CTG AAC ACC TTC CAG GAA TTC TTC GGC CTG AGT AAC TGT Val Ile Leu Leu Asn Thr Phe Gln Glu Phe Phe Gly Leu Ser Asn Cys 265 270 275	870
45	GAA AGC ACC AGT CAA CTG GAC CAA GCC ACG CAG GTG ACA GAG ACT CTT Glu Ser Thr Ser Gln Leu Asp Gln Ala Thr Gln Val Thr Glu Thr Leu 280 285 290	918

## 50.

	GGG ATG ACT CAC TGC TGC ATC AAT CCC ATC ATC TAT GCC TTC GTT GGG	966
	Gly Met Thr His Cys Cys Ile Asn Pro Ile Ile Tyr Ala Phe Val Gly	
	295 300 305	
5	GAG AAG TTC AGA AGC CTT TTT CAC ATA GCT CTT GGC TGT AGG ATT GCC	1014
	Glu Lys Phe Arg Ser Leu Phe His Ile Ala Leu Gly Cys Arg Ile Ala	
	310 315 320 325	
10	CCA CTC CAA AAA CCA GTG TGT GGA GGT CCA GGA GTG AGA CCA GGA AAG	1062
	Pro Leu Gln Lys Pro Val Cys Gly Gly Pro Gly Val Arg Pro Gly Lys	
	330 335 340	
15	AAT GTG AAA GTG ACT ACA CAA GGA CTC CTC GAT GGT CGT GGA AAA GGA	1110
	Asn Val Lys Val Thr Thr Gln Gly Leu Leu Asp Gly Arg Gly Lys Gly	
	345 350 355	
20	AAG TCA ATT GGC AGA GCC CCT GAA GCC AGT CTT CAG GAC AAA GAA GGA	1158
	Lys Ser Ile Gly Arg Ala Pro Glu Ala Ser Leu Gln Asp Lys Glu Gly	
	360 365 370	
	GCC TAGAGACAGA AATGACAGAT CTCTGCTTTG GAAATCACAC GTCTGGCTTC	1211
	Ala	
25	ACAGATGTGT GATTACAGT GTGAATCTTG GTGTCTACGT TACCAGGCAG GAAGGCTGAG	1271
	AGGAGAGAGA CTCAGCTGC GTTGAAAC AGTATTTTCC AAACACCTT CCAGTTCCTC	1331
30	ATTTTGAAT ACAGGCATAG AGTTCAGACT TTTTAAAT AGTAAAAATA AAATTAAAGC	1391
	TGAAACTGC AACTTGTAAG TGTGGTAAAG AGTTAGTTTG AGTTGCTATC ATGTCAAACG	1451
	TGAAATGCT GTATTAGTCA CAGAGATAAT TCTAGCTTTG AGCTTAAGAA TTTTGAGCAG	1511
35	GTGGTATGTT TGGGAGACTG CTGAGTCAAC CCAATAGTTG TTGATTGGCA GGAGTTGGAA	1571
	GTGTGTGATC TGTGGGCACA TTAGCCTATG TGCATGCAGC ATCTAAGTAA TGATGTCGTT	1631
	TGAATCACAG TATACGCTCC ATCGCTGTCA TCTCAGCTGG ATCTCCATTC TCTCAGGCTT	1691
40	GCTGCCAAAA GCCTTTGTG TTTTGTGTTG TATCATTATG AAGTCATGCG TTTAATCACA	1751
	TTGAGTGTT TCAGTGCTTC GCAGATGCCC TTGATGCTCA TATTGTTCCC TAATTGCCA	1811
45	GTGGGAACCT CTAATCAAA TTGGCTTCTA ATCAAAGCTT TTAACCECTA TTGGTAAAGA	1871
	ATGGAAGGTG GAGAAGCTCC CTGAAGTAAG CAAAGACTTT CCTCTTAGTC GAGCCAAGTT	1931
	AAGAATGTTT TTAGTTGCC CAGTGTGTTT CTGATCTGAT GCAAGCAAGA AACACTGGGC	1991

51.

TTCTAGAACC AGGCAACTTG GGAAGTAGAC TCCCAAGCTG GACTATGGCT CTACTTTCAG 2051  
 GCCACATGGC TAAAGAAGGT TTCAGAAAGA AGTGGGGACA GAGCAGAACT TTCACCTTCA 2111  
 5 TATATTTGTA TGATCCTAAT GAATGCATAA AATGTTAAGT TGATGGTGAT GAAATGTAAA 2171  
 TACTGTTTTT AACCACTATG ATTTGGAAAA TAAATCAATG CTATACTAT GTTGATAAAA 2231  
 G 2232  
 10

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:  
 15 (A) LENGTH: 374 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein  
 20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Leu Ser Thr Ser Arg Ser Arg Phe Ile Arg Asn Thr Asn Glu Ser  
 1 5 10 15  
 25 Gly Glu Glu Val Thr Thr Phe Phe Asp Tyr Asp Tyr Gly Ala Pro Cys  
 20 25 30  
 His Lys Phe Asp Val Lys Gln Ile Gly Ala Gln Leu Leu Pro Pro Leu  
 30 35 40 45  
 Tyr Ser Leu Val Phe Ile Phe Gly Phe Val Gly Asn Met Leu Val Val  
 50 55 60  
 35 Leu Ile Leu Ile Asn Cys Lys Lys Leu Lys Cys Leu Thr Asp Ile Tyr  
 65 70 75 80  
 Leu Leu Asn Leu Ala Ile Ser Asp Leu Leu Phe Leu Ile Thr Leu Pro  
 85 90 95  
 40 Leu Trp Ala His Ser Ala Ala Asn Glu Trp Val Phe Gly Asn Ala Met  
 100 105 110  
 Cys Lys Leu Phe Thr Gly Leu Tyr His Ile Gly Tyr Phe Gly Gly Ile  
 45 115 120 125  
 Phe Phe Ile Ile Leu Leu Thr Ile Asp Arg Tyr Leu Ala Ile Val His  
 130 135 140

52.

Ala Val Phe Ala Leu Lys Ala Arg Thr Val Thr Phe Gly Val Val Thr  
 145 150 155 160

5 Ser Val Ile Thr Trp Leu Val Ala Val Phe Ala Ser Val Pro Gly Ile  
 165 170 175

Ile Phe Thr Lys Cys Gln Lys Glu Asp Ser Val Tyr Val Cys Gly Pro  
 180 185 190

10 Tyr Phe Pro Arg Gly Trp Asn Asn Phe His Thr Ile Met Arg Asn Ile  
 195 200 205

Leu Gly Leu Val Leu Pro Leu Leu Ile Met Val Ile Cys Tyr Ser Gly  
 210 215 220

15 Ile Leu Lys Thr Leu Leu Arg Cys Arg Asn Glu Lys Lys Arg His Arg  
 225 230 235 240

20 Ala Val Arg Val Ile Phe Thr Ile Met Ile Val Tyr Phe Leu Phe Trp  
 245 250 255

Thr Pro Tyr Asn Ile Val Ile Leu Leu Asn Thr Phe Gln Glu Phe Phe  
 260 265 270

25 Gly Leu Ser Asn Cys Glu Ser Thr Ser Gln Leu Asp Gln Ala Thr Gln  
 275 280 285

Val Thr Glu Thr Leu Gly Met Thr His Cys Cys Ile Asn Pro Ile Ile  
 290 295 300

30 Tyr Ala Phe Val Gly Glu Lys Phe Arg Ser Leu Phe His Ile Ala Leu  
 305 310 315 320

Gly Cys Arg Ile Ala Pro Leu Gln Lys Pro Val Cys Gly Gly Pro Gly  
 325 330 335

35 Val Arg Pro Gly Lys Asn Val Lys Val Thr Thr Gln Gly Leu Leu Asp  
 340 345 350

40 Gly Arg Gly Lys Gly Lys Ser Ile Gly Arg Ala Pro Glu Ala Ser Leu  
 355 360 365

Gln Asp Lys Glu Gly Ala  
 370

45

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1979 base pairs

53.

(B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

10 (iv) ANTI-SENSE: NO

(ix) FEATURE:

(A) NAME/KEY: CDS

15 (B) LOCATION: 81..1160

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

20	CAGGACTGCC TGAGACAAGC CACAAGCTGA ACAGAGAAAG TGGATTGAAC AAGGACGCAT	60
	TTCCCCAGTA CATCCACAAC ATG CTG TCC ACA TCT CGT TCT CGG TTT ATC	110
	Met Leu Ser Thr Ser Arg Ser Arg Phe Ile	
	1 5 10	
25	AGA AAT ACC AAC GAG AGC GGT GAA GAA GTC ACC ACC TTT TTT GAT TAT	158
	Arg Asn Thr Asn Glu Ser Gly Glu Glu Val Thr Thr Phe Phe Asp Tyr	
	15 20 25	
30	GAT TAC GGT GCT CCC TGT CAT AAA TTT GAC GTG AAG CAA ATT GGG GCC	206
	Asp Tyr Gly Ala Pro Cys His Lys Phe Asp Val Lys Gln Ile Gly Ala	
	30 35 40	
35	CAA CTC CTG CCT CCG CTC TAC TCG CTG GTG TTC ATC TTT GGT TTT GTG	254
	Gln Leu Leu Pro Pro Leu Tyr Ser Leu Val Phe Ile Phe Gly Phe Val	
	45 50 55	
40	GGC AAC ATG CTG GTC GTC CTC ATC TTA ATA AAC TGC AAA AAG CTG AAG	302
	Gly Asn Met Leu Val Val Leu Ile Leu Ile Asn Cys Lys Lys Leu Lys	
	60 65 70	
	TGC TTG ACT GAC ATT TAC CTG CTC AAC CTG GCC ATC TCT GAT CTG CTT	350
	Cys Leu Thr Asp Ile Tyr Leu Leu Asn Leu Ala Ile Ser Asp Leu Leu	
	75 80 85 90	
45	TTT CTT ATT ACT CTC CCA TTG TGG GCT CAC TCT GCT GCA AAT GAG TGG	398
	Phe Leu Ile Thr Leu Pro Leu Trp Ala His Ser Ala Ala Asn Glu Trp	
	95 100 105	

54.

	GTC TTT GGG AAT GCA ATG TGC AAA TTA TTC ACA GGG CTG TAT CAC ATC Val Phe Gly Asn Ala Met Cys Lys Leu Phe Thr Gly Leu Tyr His Ile 110 115 120	446
5	GGT TAT TTT GGC GGA ATC TTC TTC ATC ATC CTC CTG ACA ATC GAT AGA Gly Tyr Phe Gly Gly Ile Phe Phe Ile Ile Leu Leu Thr Ile Asp Arg 125 130 135	494
10	TAC CTG GCT ATT GTC CAT GCT GTG TTT GCT TTA AAA GCC AGG ACG GTC Tyr Leu Ala Ile Val His Ala Val Phe Ala Leu Lys Ala Arg Thr Val 140 145 150	542
15	ACC TTT GGG GTG GTG ACA AGT GTG ATC ACC TGG TTG GTG GCT GTG TTT Thr Phe Gly Val Val Thr Ser Val Ile Thr Trp Leu Val Ala Val Phe 155 160 165 170	590
20	GCT TCT GTC CCA GGA ATC ATC TTT ACT AAA TGC CAG AAA GAA GAT TCT Ala Ser Val Pro Gly Ile Ile Phe Thr Lys Cys Gln Lys Glu Asp Ser 175 180 185	638
	GTT TAT GTC TGT GGC CCT TAT TTT CCA CGA GGA TGG AAT AAT TTC CAC Val Tyr Val Cys Gly Pro Tyr Phe Pro Arg Gly Trp Asn Asn Phe His 190 195 200	686
25	ACA ATA ATG AGG AAC ATT TTG GGG CTG GTC CTG CCG CTG CTC ATC ATG Thr Ile Met Arg Asn Ile Leu Gly Leu Val Leu Pro Leu Leu Ile Met 205 210 215	734
30	GTC ATC TGC TAC TCG GGA ATC CTG AAA ACC CTG CTT CGG TGT CGA AAC Val Ile Cys Tyr Ser Gly Ile Leu Lys Thr Leu Leu Arg Cys Arg Asn 220 225 230	782
35	GAG AAG AAG AGG CAT AGG GCA GTG AGA GTC ATC TTC ACC ATC ATG ATT Glu Lys Lys Arg His Arg Ala Val Arg Val Ile Phe Thr Ile Met Ile 235 240 245 250	830
40	GTT TAC TTT CTC TTC TGG ACT CCC TAT AAC ATT GTC ATT CTC CTG AAC Val Tyr Phe Leu Phe Trp Thr Pro Tyr Asn Ile Val Ile Leu Leu Asn 255 260 265	878
	ACC TTC CAG GAA TTC TTC GGC CTG AGT AAC TGT GAA AGC ACC AGT CAA Thr Phe Gln Glu Phe Phe Gly Leu Ser Asn Cys Glu Ser Thr Ser Gln 270 275 280	926
45	CTG GAC CAA GCC ACG CAG GTG ACA GAG ACT CTT GGG ATG ACT CAC TGC Leu Asp Gln Ala Thr Gln Val Thr Glu Thr Leu Gly Met Thr His Cys 285 290 295	974



55.

	TGC ATC AAT CCC ATC ATC TAT GCC TTC GTT GGG GAG AAG TTC AGA AGG Cys Ile Asn Pro Ile Ile Tyr Ala Phe Val Gly Glu Lys Phe Arg Arg 300 305 310	1022
5	TAT CTC TCG GTG TTC TTC CGA AAG CAC ATC ACC AAG CGC TTC TGC AAA Tyr Leu Ser Val Phe Phe Arg Lys His Ile Thr Lys Arg Phe Cys Lys 315 320 325 330	1070
10	CAA TGT CCA GTT TTC TAC AGG GAG ACA GTG GAT GGA GTG ACT TCA ACA Gln Cys Pro Val Phe Tyr Arg Glu Thr Val Asp Gly Val Thr Ser Thr 335 340 345	1118
15	AAC ACG CCT TCC ACT GGG GAG CAG GAA GTC TCG GCT GGT TTA Asn Thr Pro Ser Thr Gly Glu Gln Glu Val Ser Ala Gly Leu 350 355 360	1160
20	TAAAACGAGG AGCAGTTTGA TTGTTGTTTA TAAAGGGAGA TAACAATCTG TATATAACAA CAAACCTCAA GGGTTTGTG AACAAATAGAA ACCTGTAAAG CAGGTGCCCA GGAACCTCAG GGCTGTGTGT ACTAATACAG ACTATGTCAC CCAATGCATA TCCAACATGT GCTCAGGGAA	1220 1280 1340
25	TAATCCAGAA AAAGTGTGG TAGAGACTTT GACTCTCCAG AAAGCTCATE TCAGTCCTG AAAAATGCCT CATTACCTTG TGCTAATCCT CTTTTCTAG TCTTCATAAT TTCTTCACTC AATCTCTGAT TCTGTCAATG TCTTGAATC AAGGGCCAGC TGGAGGTGAA GAAGAGAATG	1400 1460 1520
30	TGACAGGCAC AGATGAATGG GAGTGAGGGA TAGTGGGGTC AGGGCTGAGA GGAGAAGGAG GGAGACATGA GCATGGCTGA GCCTGGACAA AGACAAAGGT GAGCAAAGGG CTCACGCATT CAGCCAGGAG ATGATACTGG TCCTTAGCCC CATCTGCCAC GTGTATTTAA CCTTGAAGGG	1580 1640 1700
35	TTCACCAGGT CAGGGAGAGT TTGGGAACTG CAATAACCTG GGAGTTTTGG TGGAGTCCGA TGATTCTCTT TTGCATAAGT GCATGACATA TTTTTCCTT ATTACAGTTT ATCTATGGCA	1760 1820
40	CCCATGCACC TTACATTTGA AATCTATGAA ATATCATGCT CCAITGTTCA GATGCTTCTT AGGCCACATC CCCCTGTCTA AAAATTCAGA AAATTTTGT TTATAAAGA TGCATTATCT ATGATATGCT AATATATGTA TATGCAATAT AAAATTTAG	1880 1940 1979
45		

56.

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 360 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Leu Ser Thr Ser Arg Ser Arg Phe Ile Arg Asn Thr Asn Glu Ser  
1 5 10 15

15 Gly Glu Glu Val Thr Thr Phe Phe Asp Tyr Asp Tyr Gly Ala Pro Cys  
20 25 30

His Lys Phe Asp Val Lys Gln Ile Gly Ala Gln Leu Leu Pro Pro Leu  
35 40 45

20 Tyr Ser Leu Val Phe Ile Phe Gly Phe Val Gly Asn Met Leu Val Val  
50 55 60

---

25 Leu Ile Leu Ile Asn Cys Lys Lys Leu Lys Cys Leu Thr Asp Ile Tyr  
65 70 75 80

Leu Leu Asn Leu Ala Ile Ser Asp Leu Leu Phe Leu Ile Thr Leu Pro  
85 90 95

30 Leu Trp Ala His Ser Ala Ala Asn Glu Trp Val Phe Gly Asn Ala Met  
100 105 110

Cys Lys Leu Phe Thr Gly Leu Tyr His Ile Gly Tyr Phe Gly Gly Ile  
115 120 125

35 Phe Phe Ile Ile Leu Leu Thr Ile Asp Arg Tyr Leu Ala Ile Val His  
130 135 140

Ala Val Phe Ala Leu Lys Ala Arg Thr Val Thr Phe Gly Val Val Thr  
40 145 150 155 160

Ser Val Ile Thr Trp Leu Val Ala Val Phe Ala Ser Val Pro Gly Ile  
165 170 175

45 Ile Phe Thr Lys Cys Gln Lys Glu Asp Ser Val Tyr Val Cys Gly Pro  
180 185 190

Tyr Phe Pro Arg Gly Trp Asn Asn Phe His Thr Ile Met Arg Asn Ile  
195 200 205

57.

Leu Gly Leu Val Leu Pro Leu Leu Ile Met Val Ile Cys Tyr Ser Gly  
 210 215 220  
 Ile Leu Lys Thr Leu Leu Arg Cys Arg Asn Glu Lys Lys Arg His Arg  
 5 225 230 235 240  
 Ala Val Arg Val Ile Phe Thr Ile Met Ile Val Tyr Phe Leu Phe Trp  
 245 250 255  
 10 Thr Pro Tyr Asn Ile Val Ile Leu Leu Asn Thr Phe Gln Glu Phe Phe  
 260 265 270  
 Gly Leu Ser Asn Cys Glu Ser Thr Ser Gln Leu Asp Gln Ala Thr Gln  
 275 280 285  
 15 Val Thr Glu Thr Leu Gly Met Thr His Cys Cys Ile Asn Pro Ile Ile  
 290 295 300  
 Tyr Ala Phe Val Gly Glu Lys Phe Arg Arg Tyr Leu Ser Val Phe Phe  
 20 305 310 315 320  
 Arg Lys His Ile Thr Lys Arg Phe Cys Lys Gln Cys Pro Val Phe Tyr  
 325 330 335

25 Arg Glu Thr Val Asp Gly Val Thr Ser Thr Asn Thr Pro Ser Thr Gly  
 340 345 350  
 Glu Gln Glu Val Ser Ala Gly Leu  
 355 360

30  
 (2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 355 amino acids  
 35 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

40 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

45  
 (x1) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met Glu Thr Pro Asn Thr Thr Glu Asp Tyr Asp Thr Thr Thr Glu Phe  
 1 5 10 15

58.

	Asp Tyr Gly Asp Ala Thr Pro Cys Gln Lys Val Asn Glu Arg Ala Phe
	20 25 30
5	Gly Ala Gln Leu Leu Pro Pro Leu Tyr Ser Leu Val Phe Val Ile Gly
	35 40 45
	Leu Val Gly Asn Ile Leu Val Val Leu Val Leu Val Gln Tyr Lys Arg
	50 55 60
10	Leu Lys Asn Met Thr Ser Ile Tyr Leu Leu Asn Leu Ala Ile Ser Asp
	65 70 75 80
	Leu Leu Phe Leu Phe Thr Leu Pro Phe Trp Ile Asp Tyr Lys Leu Lys
	85 90 95
15	Asp Asp Trp Val Phe Gly Asp Ala Met Cys Lys Ile Leu Ser Gly Phe
	100 105 110
	Tyr Tyr Thr Gly Leu Tyr Ser Glu Ile Phe Phe Ile Ile Leu Leu Thr
20	115 120 125
	Ile Asp Arg Tyr Leu Ala Ile Val His Ala Val Phe Ala Leu Arg Ala
	130 135 140
25	Arg Thr Val Thr Phe Gly Val Ile Thr Ser Ile Ile Ile Trp Ala Leu
	145 150 155 160
	Ala Ile Leu Ala Ser Met Pro Gly Leu Tyr Phe Ser Lys Thr Gln Trp
	165 170 175
30	Glu Phe Thr His His Thr Cys Ser Leu His Phe Pro His Glu Ser Leu
	180 185 190
	Arg Glu Trp Lys Leu Phe Gln Ala Leu Lys Leu Asn Leu Phe Gly Leu
35	195 200 205
	Val Leu Pro Leu Leu Val Met Ile Ile Cys Tyr Thr Gly Ile Ile Lys
	210 215 220
40	Ile Leu Leu Arg Arg Pro Asn Glu Lys Lys Ser Lys Ala Val Arg Leu
	225 230 235 240
	Ile Phe Val Ile Met Ile Ile Phe Phe Leu Phe Trp Thr Pro Tyr Asn
	245 250 255
45	Leu Thr Ile Leu Ile Ser Val Phe Gln Asp Phe Leu Phe Thr His Glu
	260 265 270

59.

Cys Glu Gln Ser Arg His Leu Asp Leu Ala Val Gln Val Thr Glu Val  
 275 280 285  
 Ile Ala Tyr Thr His Cys Cys Val Asn Pro Val Ile Tyr Ala Phe Val  
 5 290 295 300  
 Gly Glu Arg Phe Arg Lys Tyr Leu Arg Gln Leu Phe His Arg Arg Val  
 305 310 315 320  
 10 Ala Val His Leu Val Lys Trp Leu Pro Phe Leu Ser Val Asp Arg Leu  
 325 330 335  
 Glu Arg Val Ser Ser Thr Ser Pro Ser Thr Gly Glu His Glu Leu Ser  
 340 345 350  
 15 Ala Gly Phe  
 355  
 20 (2) INFORMATION FOR SEQ ID NO:6:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 352 amino acids  
 (B) TYPE: amino acid  
 25 (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: protein  
 (iii) HYPOTHETICAL: NO  
 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:  
 Met Glu Gly Ile Ser Ile Tyr Thr Ser Asp Asn Tyr Thr Glu Glu Met  
 1 5 10 15  
 35 Gly Ser Gly Asp Tyr Asp Ser Met Lys Glu Pro Cys Phe Arg Glu Glu  
 20 25 30  
 Asn Ala Asn Phe Asn Lys Ile Phe Leu Pro Tyr Ile Tyr Ser Ile Ile  
 40 35 40 45  
 Phe Leu Tyr Gly Ile Val Gly Asn Gly Leu Val Ile Leu Val Met Gly  
 50 55 60  
 45 Tyr Gln Lys Lys Leu Arg Ser Met Thr Asp Lys Tyr Arg Leu His Leu  
 65 70 75 80

60.

	Ser Val Ala Asp Leu Leu Phe Val Ile Thr Leu Pro Phe Trp Ala Val
	85 90 95
5	Asp Ala Val Ala Asn Trp Tyr Phe Gly Asn Phe Leu Cys Lys Ala Val
	100 105 110
	His Val Ile Tyr Thr Val Asn Leu Tyr Ser Ser Val Leu Ile Leu Ala
	115 120 125
10	Phe Ile Ser Leu Asp Arg Tyr Leu Ala Ile Val His Ala Thr Asn Ser
	130 135 140
	Gln Arg Pro Arg Lys Leu Leu Ala Glu Lys Val Val Tyr Val Gly Val
15	145 150 155 160
	Trp Ile Pro Ala Leu Leu Leu Thr Ile Pro Asp Phe Ile Phe Ala Asn
	165 170 175
20	Val Ser Glu Ala Asp Asp Arg Tyr Ile Cys Asp Arg Phe Tyr Pro Asn
	180 185 190
	Asp Leu Trp Val Val Val Phe Gln Phe Gln His Ile Met Val Gly Leu
	195 200 205
25	Ile Leu Pro Gly Ile Val Ile Leu Phe Cys Tyr Cys Ile Ile Ile Ser
	210 215 220
	Lys Leu Ser His Ser Lys Gly His Gln Lys Arg Lys Ala Leu Lys Tyr
30	225 230 235 240
	Tyr Val Ile Leu Ile Leu Ala Phe Phe Ala Cys Trp Leu Pro Tyr Tyr
	245 250 255
35	Ile Gly Ile Ser Ile Asp Ser Phe Ile Leu Leu Glu Ile Ile Lys Gln
	260 265 270
	Gly Cys Glu Phe Glu Asn Thr Val His Lys Trp Ile Ser Ile Thr Glu
	275 280 285
40	Ala Leu Ala Phe Phe His Cys Cys Leu Asn Pro Ile Leu Tyr Ala Phe
	290 295 300
	Leu Gly Ala Lys Phe Lys Tyr Ser Ala Gln His Ala Leu Thr Ser Val
45	305 310 315 320
	Ser Arg Gly Ser Ser Leu Lys Ile Leu Ser Lys Gly Lys Arg Gly Gly
	325 330 335

61.

His Ser Ser Val Ser Thr Glu Ser Glu Ser Ser Ser Phe His Ser Ser  
 340 345 350

## 5 (2) INFORMATION FOR SEQ ID NO:7:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 350 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

## 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Met Ser Asn Ile Thr Asp Pro Gln Met Trp Asp Phe Asp Asp Leu Asn  
 1 5 10 15

---

Phe Thr Gly Met Pro Pro Ala Asp Glu Asp Tyr Ser Pro Cys Met Leu  
 20 25 30

Glu Thr Glu Thr Leu Asn Lys Tyr Val Val Ile Ile Ala Tyr Ala Leu  
 35 40 45

Val Phe Leu Leu Ser Leu Leu Gly Asn Ser Leu Val Met Leu Val Ile  
 50 55 60

Leu Tyr Ser Arg Val Gly Arg Ser Val Thr Asp Val Tyr Leu Leu Asn  
 65 70 75 80

Leu Ala Leu Ala Asp Leu Leu Phe Ala Leu Thr Leu Pro Ile Trp Ala  
 85 90 95

Ala Ser Lys Val Asn Gly Trp Ile Phe Gly Thr Phe Leu Cys Lys Val  
 100 105 110

Val Ser Leu Leu Lys Glu Val Asn Phe Tyr Ser Gly Ile Leu Leu Leu  
 115 120 125

Ala Cys Ile Ser Val Asp Arg Tyr Leu Ala Ile Val His Ala Thr Arg  
 130 135 140

62.

	Thr	Leu	Thr	Gln	Lys	Arg	His	Leu	Val	Lys	Phe	Val	Cys	Leu	Gly	Cys	
	145					150					155					160	
5	Trp	Gly	Leu	Ser	Met	Asn	Leu	Ser	Leu	Pro	Phe	Phe	Leu	Phe	Arg	Gln	
					165					170					175		
	Ala	Tyr	His	Pro	Asn	Asn	Ser	Ser	Pro	Val	Cys	Tyr	Glu	Val	Leu	Gly	
					180				185						190		
10	Asn	Asp	Thr	Ala	Lys	Trp	Arg	Met	Val	Leu	Arg	Ile	Leu	Pro	His	Thr	
					195				200					205			
	Phe	Gly	Phe	Ile	Val	Pro	Leu	Phe	Val	Met	Leu	Phe	Cys	Tyr	Gly	Phe	
15					210			215					220				
	Thr	Leu	Arg	Thr	Leu	Phe	Lys	Ala	His	Met	Gly	Gln	Lys	His	Arg	Ala	
	225				230						235					240	
	Met	Arg	Val	Ile	Phe	Ala	Val	Val	Leu	Ile	Phe	Leu	Leu	Cys	Trp	Leu	
20					245					250					255		
	Pro	Tyr	Asn	Leu	Val	Leu	Leu	Ala	Asp	Thr	Leu	Met	Arg	Thr	Gln	Val	
					260				265					270			
25	Ile	Gln	Glu	Thr	Cys	Glu	Arg	Arg	Asn	Asn	Ile	Gly	Arg	Ala	Leu	Asp	
					275				280					285			
	Ala	Thr	Glu	Ile	Leu	Gly	Phe	Leu	His	Ser	Cys	Leu	Asn	Pro	Ile	Ile	
30					290			295					300				
	Tyr	Ala	Phe	Ile	Gly	Gln	Asn	Phe	Arg	His	Gly	Phe	Leu	Lys	Ile	Leu	
	305				310						315				320		
	Ala	Met	His	Gly	Leu	Val	Ser	Lys	Glu	Phe	Leu	Ala	Arg	His	Arg	Val	
35					325						330				335		
	Thr	Ser	Tyr	Thr	Ser	Ser	Ser	Val	Asn	Val	Ser	Ser	Asn	Leu			
					340				345					350			

40 (2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 355 amino acids

(B) TYPE: amino acid

45 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO



63.

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

5	Met Glu Ser Asp Ser Phe Glu Asp Phe Trp Lys Gly Glu Asp Leu Ser
	1                      5                      10                      15
	Asn Tyr Ser Tyr Ser Ser Thr Leu Pro Pro Phe Leu Leu Asp Ala Ala
	20                      25                      30
10	Pro Cys Glu Pro Glu Ser Leu Glu Ile Asn Lys Tyr Phe Val Val Ile
	35                      40                      45
	Ile Tyr Ala Leu Val Phe Leu Leu Ser Leu Leu Gly Asn Ser Leu Val
15	50                      55                      60
	Met Leu Val Ile Leu Tyr Ser Arg Val Gly Arg Ser Val Thr Asp Val
	65                      70                      75                      80
	Tyr Leu Leu Asn Leu Ala Leu Ala Asp Leu Leu Phe Ala Leu Thr Leu
20	85                      90                      95
	Pro Ile Trp Ala Ala Ser Lys Val Asn Gly Trp Ile Phe Gly Thr Phe
	100                      105                      110
25	Leu Cys Lys Val Val Ser Leu Leu Lys Glu Val Asn Phe Tyr Ser Gly
	115                      120                      125
	Ile Leu Leu Leu Ala Cys Ile Ser Val Asp Arg Tyr Leu Ala Ile Val
30	130                      135                      140
	His Ala Thr Arg Thr Leu Thr Gln Lys Arg Tyr Leu Val Lys Phe Ile
	145                      150                      155                      160
	Cys Leu Ser Ile Trp Gly Leu Ser Leu Leu Leu Ala Leu Pro Val Leu
35	165                      170                      175
	Leu Phe Arg Arg Thr Val Tyr Ser Ser Asn Val Ser Pro Ala Cys Tyr
	180                      185                      190
40	Glu Asp Met Gly Asn Asn Thr Ala Asn Trp Arg Met Leu Leu Arg Ile
	195                      200                      205
	Leu Pro Gln Ser Phe Gly Phe Ile Val Pro Leu Leu Ile Met Leu Phe
45	210                      215                      220
	Cys Tyr Gly Phe Thr Leu Arg Thr Leu Phe Lys Ala His Met Gly Gln
	225                      230                      235                      240

64.

Lys His Arg Ala Met Arg Val Ile Phe Ala Val Val Leu Ile Phe Leu  
                             245                            250                            255  
 5      Leu Cys Trp Leu Pro Tyr Asn Leu Val Leu Leu Ala Asp Thr Leu Met  
                             260                            265                            270  
       Arg Thr Gln Val Ile Gln Glu Thr Cys Glu Arg Arg Asn His Ile Asp  
                             275                            280                            285  
 10     Arg Ala Leu Asp Ala Thr Glu Ile Leu Gly Ile Leu His Ser Cys Leu  
                             290                            295                            300  
       Asn Pro Leu Ile Tyr Ala Phe Ile Gly Gln Lys Phe Arg His Gly Leu  
 15     305                            310                            315                            320  
       Leu Lys Ile Leu Ala Ile His Gly Leu Ile Ser Lys Asp Ser Leu Pro  
                             325                            330                            335  
 20     Lys Asp Ser Arg Pro Ser Phe Val Gly Ser Ser Ser Gly His Thr Ser  
                             340                            345                            350  
       Thr Thr Leu  
                             355

25 (2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 27 base pairs  
 30     (B) TYPE: nucleic acid  
     (C) STRANDEDNESS: single  
     (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (synthetic)

35 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

40

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CGCTCGAGAC CTRKMDTKK CYGACCT

27

45 (2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 31 base pairs  
     (B) TYPE: nucleic acid

65.

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: DNA (synthetic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GCGAATTCTG GACRATGGCC AGGTAVCKGT C

31

15

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

20

(ii) MOLECULE TYPE: peptide

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Asn Leu Ala Ile Ser Asp Leu

1

5

30

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: peptide

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Asp Arg Tyr Leu Ala Ile Val

1

5

45

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31 amino acids

66.

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

10

Ile Phe Phe Ile Ile Leu Leu Thr Ile Asp Arg Tyr Leu Ala Ile Val

1

5

10

15

His Ala Val Phe Ala Leu Lys Ala Arg Thr Val Thr Phe Gly Val

20

25

30

15

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31 amino acids

(B) TYPE: amino acid

20

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Ile Phe Phe Ile Ile Leu Leu Thr Ile Asp Arg Tyr Leu Ala Ile Val

1

5

10

15

30

His Ala Val Phe Ala Leu Arg Ala Arg Thr Val Thr Phe Gly Val

20

25

30

67.

WE CLAIM:

1. An isolated DNA sequence that codes on expression for MCP-1R.
- 5 2. A polypeptide free of association with other polypeptides and comprising the mature amino acid sequence of Fig. 1 (SEQ ID NO:2) or Fig. 2 (SEQ ID NO:4).
3. A polypeptide that is free of association with other polypeptides and is  
10 encoded by a DNA sequence selected from the group consisting of:
  - i) the DNA sequence of Figure 1 (SEQ ID NO:1) or Figure 2 (SEQ ID NO:3);
  - 15 ii) a DNA capable of hybridizing under stringent conditions to a DNA of i); and
  - iii) a DNA differing from the DNAs of i) and ii) in coding sequence due to degeneracy of the genetic code.
4. A DNA sequence of claim 1 wherein the isolated DNA comprises a  
20 cDNA.
5. An expression vector containing a DNA sequence of claim 1.
6. A cell transformed with a DNA sequence of claim 1, said DNA sequence  
25 being arranged in operative association with an expression control sequence capable of directing replication and expression of said DNA sequence.
7. A cell according to claim 6 wherein said cell is a mammalian or bacterial cell.

30

68.

8. A process for producing a MCP-1R protein comprising culturing a cell of claim 6 in a suitable culture medium and isolating said MCP-1R protein from said cell.

5 9. A method for identifying antagonists of the MCP-1 receptor comprising the steps of:

a) transfecting a mammalian cell line with an expression vector comprising nucleic acid sequences encoding the N-terminal domain of MCP-1 receptor;

10 b) culturing said cell line in a culture medium, whereby said receptor domain is expressed stably;

c) adding an effective amount of an organic compound to said culture medium, sufficient to block the binding of MCP-1 to said receptor domain; and

d) detecting said loss in binding.

15

10. The method of claim 9, wherein said N terminal domain is expressed in combination with other MCP-1 receptor extracellular domains.

11. The method of claim 9, wherein said N terminal domain is expressed as a  
20 portion of the native MCP-1 receptor.

12. The method of claim 9, wherein said detection is by an immunoassay.

13. The method of claim 9, wherein said MCP-1 is labeled.

25

14. A pharmaceutical composition useful in the treatment of disease characterized by monocytic infiltrates comprising a therapeutically effective amount of an MCP-1 receptor antagonist identified using the method of claim 9 in a pharmaceutically acceptable vehicle.

30

1/14

## FIG. 1A

GGATTGAACA AGGACGCATT TCCCCAGTAC ATCCACAAC ATG CTG TCC ACA TCT	54
Met Leu Ser Thr Ser	
1 5	
CGT TCT CGG TTT ATC AGA AAT ACC AAC GAG AGC GGT GAA GAA GTC ACC	102
Arg Ser Arg Phe Ile Arg Asn Thr Asn Glu Ser Gly Glu Glu Val Thr	
10 15 20	
ACC TTT TTT GAT TAT GAT TAC GGT GCT CCC TGT CAT AAA TTT GAC GTG	150
Thr Phe Phe Asp Tyr Asp Tyr Gly Ala Pro Cys His Lys Phe Asp Val	
25 30 35	
AAG CAA ATT GGG GCC CAA CTC CTG CCT CCG CTC TAC TCG CTG GTG TTC	198
Lys Gln Ile Gly Ala Gln Leu Leu Pro Pro Leu Tyr Ser Leu Val Phe	
40 45 50	
ATC TTT GGT TTT GTG GGC AAC ATG CTG GTC GTC CTC ATC TTA ATA AAC	246
Ile Phe Gly Phe Val Gly Asn Met Leu Val Val Leu Ile Leu Ile Asn	
55 60 65	
TGC AAA AAG CTG AAG TGC TTG ACT GAC ATT TAC CTG CTC AAC CTG GCC	294
Cys Lys Lys Leu Lys Cys Leu Thr Asp Ile Tyr Leu Leu Asn Leu Ala	
70 75 80 85	
ATC TCT GAT CTG CTT TTT CTT ATT ACT CTC CCA TTG TGG GCT CAC TCT	342
Ile Ser Asp Leu Leu Phe Leu Ile Thr Leu Pro Leu Trp Ala His Ser	
90 95 100	
GCT GCA AAT GAG TGG GTC TTT GGG AAT GCA ATG TGC AAA TTA TTC ACA	390
Ala Ala Asn Glu Trp Val Phe Gly Asn Ala Met Cys Lys Leu Phe Thr	
105 110 115	
GGG CTG TAT CAC ATC GGT TAT TTT GGC GGA ATC TTC TTC ATC ATC CTC	438
Gly Leu Tyr His Ile Gly Tyr Phe Gly Gly Ile Phe Phe Ile Ile Leu	
120 125 130	
CTG ACA ATC GAT AGA TAC CTG GCT ATT GTC CAT GCT GTG TTT GCT TTA	486
Leu Thr Ile Asp Arg Tyr Leu Ala Ile Val His Ala Val Phe Ala Leu	
135 140 145	

2/14

## FIG. 1B

AAA GCC AGG ACG GTC ACC TTT GGG GTG GTG ACA AGT GTG ATC ACC TGG	534
Lys Ala Arg Thr Val Thr Phe Gly Val Val Thr Ser Val Ile Thr Trp	
150                      155                      160                      165	
TTG GTG GCT GTG TTT GCT TCT GTC CCA GGA ATC ATC TTT ACT AAA TGC	582
Leu Val Ala Val Phe Ala Ser Val Pro Gly Ile Ile Phe Thr Lys Cys	
170                      175                      180	
CAG AAA GAA GAT TCT GTT TAT GTC TGT GGC CCT TAT TTT CCA CGA GGA	630
Gln Lys Glu Asp Ser Val Tyr Val Cys Gly Pro Tyr Phe Pro Arg Gly	
185                      190                      195	
TGG AAT AAT TTC CAC ACA ATA ATG AGG AAC ATT TTG GGG CTG GTC CTG	678
Trp Asn Asn Phe His Thr Ile Met Arg Asn Ile Leu Gly Leu Val Leu	
200                      205                      210	
CCG CTG CTC ATC ATG GTC ATC TGC TAC TCG GGA ATC CTG AAA ACC CTG	726
Pro Leu Leu Ile Met Val Ile Cys Tyr Ser Gly Ile Leu Lys Thr Leu	
215                      220                      225	
CTT CGG TGT CGA AAC GAG AAG AAG AGG CAT AGG GCA GTG AGA GTC ATC	774
Leu Arg Cys Arg Asn Glu Lys Lys Arg His Arg Ala Val Arg Val Ile	
230                      235                      240                      245	
TTC ACC ATC ATG ATT GTT TAC TTT CTC TTC TGG ACT CCC TAT AAC ATT	822
Phe Thr Ile Met Ile Val Tyr Phe Leu Phe Trp Thr Pro Tyr Asn Ile	
250                      255                      260	
GTC ATT CTC CTG AAC ACC TTC CAG GAA TTC TTC GGC CTG AGT AAC TGT	870
Val Ile Leu Leu Asn Thr Phe Gln Glu Phe Phe Gly Leu Ser Asn Cys	
265                      270                      275	
GAA AGC ACC AGT CAA CTG GAC CAA GCC ACG CAG GTG ACA GAG ACT CTT	918
Glu Ser Thr Ser Gln Leu Asp Gln Ala Thr Gln Val Thr Glu Thr Leu	
280                      285                      290	
GGG ATG ACT CAC TGC TGC ATC AAT CCC ATC ATC TAT GCC TTC GTT GGG	966
Gly Met Thr His Cys Cys Ile Asn Pro Ile Ile Tyr Ala Phe Val Gly	
295                      300                      305	



3/14

## FIG. 1C

GAG AAG TTC AGA AGC CTT TTT CAC ATA GCT CTT GGC TGT AGG ATT GCC	1014
Glu Lys Phe Arg Ser Leu Phe His Ile Ala Leu Gly Cys Arg Ile Ala	
310                      315                      320                      325	
CCA CTC CAA AAA CCA GTG TGT GGA GGT CCA GGA GTG AGA CCA GGA AAG	1062
Pro Leu Gln Lys Pro Val Cys Gly Gly Pro Gly Val Arg Pro Gly Lys	
330                      335                      340	
AAT GTG AAA GTG ACT ACA CAA GGA CTC CTC GAT GGT CGT GGA AAA GGA	1110
Asn Val Lys Val Thr Thr Gln Gly Leu Leu Asp Gly Arg Gly Lys Gly	
345                      350                      355	
AAG TCA ATT GGC AGA GCC CCT GAA GCC AGT CTT CAG GAC AAA GAA GGA	1158
Lys Ser Ile Gly Arg Ala Pro Glu Ala Ser Leu Gln Asp Lys Glu Gly	
360                      365                      370	
GCC TAGAGACAGA AATGACAGAT CTCTGCTTTG GAAATCACAC GTCTGGCTTC	1121
Ala	
ACAGATGTGT GATTCACAGT GTGAATCTTG GTGTCTACGT TACCAGGCAG GAAGGCTGAG	1271
AGGAGAGAGA CTCCAGCTGG GTTGAAAAC AGTATTTTCC AACTACCTT CCAGTTCCTC	1331
ATTTTGAAT ACAGGCATAG AGTTCAGACT TTTTTTAAAT AGTAAAAATA AAATTAAAGC	1391
TGAAAACTGC AACTTGTAAG TGTGGTAAAG AGTTAGTTTG AGTTGCTATC ATGTCAAACG	1451
TGAAAAATGCT GTATTAGTCA CAGAGATAAT TCTAGCTTTG AGCTTAAGAA TTTTGAGCAG	1511
GTGGTATGTT TGGGAGACTG CTGAGTCAAC CCAATAGTTG TTGATTGGCA GGAGTTGGAA	1571
GTGTGTGATC TGTGGGCACA TTAGCCTATG TGCATGCAGC ATCTAAGTAA TGATGTCGTT	1631
TGAATCACAG TATACGCTCC ATCGCTGTCA TCTCAGCTGG ATCTCCATTC TCTCAGGCTT	1691
GCTGCCAAAA GCCTTTTGTG TTTTGTTTTG TATCATTATG AAGTCATGCG TTTAATCACA	1751
TTCGAGTGTT TCAGTGCTTC GCAGATGTCC TTGATGCTCA TATTGTTCCC TAATTTGCCA	1811
GTGGGAAGTC CTAAATCAAA TTGGCTTCTA ATCAAAGCTT TTAAACCCTA TTGGTAAAGA	1871

4/14

*FIG. 1D*

ATGGAAGGTG GAGAAGCTCC CTGAAGTAAG CAAAGACTTT CCTCTTAGTC GAGCCAAGTT	1931
AAGAATGTTC TTATGTTGCC CAGTGTGTTT CTGATCTGAT GCAAGCAAGA AACACTGGGC	1991
TTCTAGAACC AGGCAACTTG GGAAGTAGAC TCCAAGCTG GACTATGGCT CTACTTTCAG	2051
GCCACATGGC TAAAGAAGGT TTCAGAAAGA AGTGGGGACA GAGCAGAACT TTCACCTTCA	2111
TATATTTGTA TGATCCTAAT GAATGCATAA AATGTTAAGT TGATGGTGAT GAAATGTAAA	2171
TACTGTTTTT AACAACTATG ATTTGGAAAA TAAATCAATG CTATAACTAT GTTGATAAAA	2231
G	2232

---

5/14

## FIG. 2A

CAGGACTGCC TGAGACAAGC CACAAGCTGA ACAGAGAAAG TGGATTGAAC AAGGACGCAT	60
TTCCCCAGTA CATCCACAAC ATG CTG TCC ACA TCT CGT TCT CGG TTT ATC	110
Met Leu Ser Thr Ser Arg Ser Arg Phe Ile	
1 5 10	
AGA AAT ACC AAC GAG AGC GGT GAA GAA GTC ACC ACC TTT TTT GAT TAT	158
Arg Asn Thr Asn Glu Ser Gly Glu Glu Val Thr Thr Phe Phe Asp Tyr	
15 20 25	
GAT TAC GGT GCT CCC TGT CAT AAA TTT GAC GTG AAG CAA ATT GGG GCC	206
Asp Tyr Gly Ala Pro Cys His Lys Phe Asp Val Lys Gln Ile Gly Ala	
30 35 40	
CAA CTC CTG CCT CCG CTC TAC TCG CTG GTG TTC ATC TTT GGT TTT GTG	254
Gln-Leu-Leu-Pro-Pro-Leu-Tyr-Ser-Leu-Val-Phe-Ile-Phe-Gly-Phe-Val	
45 50 55	
GGC AAC ATG CTG GTC GTC CTC ATC TTA ATA AAC TGC AAA AAG CTG AAG	302
Gly Asn Met Leu Val Val Leu Ile Leu Ile Asn Cys Lys Lys Leu Lys	
60 65 70	
TGC TTG ACT GAC ATT TAC CTG CTC AAC CTG GCC ATC TCT GAT CTG CTT	350
Cys Leu Thr Asp Ile Tyr Leu Leu Asn Leu Ala Ile Ser Asp Leu Leu	
75 80 85 90	
TTT CTT ATT ACT CTC CCA TTG TGG GCT CAC TCT GCT GCA AAT GAG TGG	398
Phe Leu Ile Thr Leu Pro Leu Trp Ala His Ser Ala Ala Asn Glu Trp	
95 100 105	
GTC TTT GGG AAT GCA ATG TGC AAA TTA TTC ACA GGG CTG TAT CAC ATC	446
Val Phe Gly Asn Ala Met Cys Lys Leu Phe Thr Gly Leu Tyr His Ile	
110 115 120	
GGT TAT TTT GGC GGA ATC TTC TTC ATC ATC CTC CTG ACA ATC GAT AGA	494
Gly Tyr Phe Gly Gly Ile Phe Phe Ile Ile Leu Leu Thr Ile Asp Arg	
125 130 135	
TAC CTG GCT ATT GTC CAT GCT GTG TTT GCT TTA AAA GCC AGG ACG GTC	542
Tyr Leu Ala Ile Val His Ala Val Phe Ala Leu Lys Ala Arg Thr Val	
140 145 150	

6/14

## FIG. 2B

ACC TTT GGG GTG GTG ACA AGT GTG ATC ACC TGG TTG GTG GCT GTG TTT	590
Thr Phe Gly Val Val Thr Ser Val Ile Thr Trp Leu Val Ala Val Phe	
155                                      160                                      165                                      170	
GCT TCT GTC CCA GGA ATC ATC TTT ACT AAA TGC CAG AAA GAA GAT TCT	638
Ala Ser Val Pro Gly Ile Ile Phe Thr Lys Cys Gln Lys Glu Asp Ser	
175                                      180                                      185	
GTT TAT GTC TGT GGC CCT TAT TTT CCA CGA GGA TGG AAT AAT TTC CAC	686
Val Tyr Val Cys Gly Pro Tyr Phe Pro Arg Gly Trp Asn Asn Phe His	
190                                      195                                      200	
ACA ATA ATG AGG AAC ATT TTG GGG CTG GTC CTG CCG CTG CTC ATC ATG	734
Thr Ile Met Arg Asn Ile Leu Gly Leu Val Leu Pro Leu Leu Ile Met	
205                                      210                                      215	
GTC ATC TGC TAC TCG GGA ATC CTG AAA ACC CTG CTT CGG TGT CGA AAC	782
Val Ile Cys Tyr Ser Gly Ile Leu Lys Thr Leu Leu Arg Cys Arg Asn	
220                                      225                                      230	
GAG AAG AAG AGG CAT AGG GCA GTG AGA GTC ATC TTC ACC ATC ATG ATT	830
Glu Lys Lys Arg His Arg Ala Val Arg Val Ile Phe Thr Ile Met Ile	
235                                      240                                      245                                      250	
GTT TAC TTT CTC TTC TGG ACT CCC TAT AAC ATT GTC ATT CTC CTG AAC	878
Val Tyr Phe Leu Phe Trp Thr Pro Tyr Asn Ile Val Ile Leu Leu Asn	
255                                      260                                      265	
ACC TTC CAG GAA TTC TTC GGC CTG AGT AAC TGT GAA AGC ACC AGT CAA	926
Thr Phe Gln Glu Phe Phe Gly Leu Ser Asn Cys Glu Ser Thr Ser Gln	
270                                      275                                      280	
CTG GAC CAA GCC ACG CAG GTG ACA GAG ACT CTT GGG ATG ACT CAC TGC	974
Leu Asp Gln Ala Thr Gln Val Thr Glu Thr Leu Gly Met Thr His Cys	
285                                      290                                      295	
TGC ATC AAT CCC ATC ATC TAT GCC TTC GTT GGG GAG AAG TTC AGA AGG	1022
Cys Ile Asn Pro Ile Ile Tyr Ala Phe Val Gly Glu Lys Phe Arg Arg	
300                                      305                                      310	

7/14

## FIG. 2C

TAT CTC TCG GTG TTC TTC CGA AAG CAC ATC ACC AAG CGC TTC TGC AAA	1070
Tyr Leu Ser Val Phe Phe Arg Lys His Ile Thr Lys Arg Phe Cys Lys	
315                        320                        325                        330	
CAA TGT CCA GTT TTC TAC AGG GAG ACA GTG GAT GGA GTG ACT TCA ACA	1118
Gln Cys Pro Val Phe Tyr Arg Glu Thr Val Asp Gly Val Thr Ser Thr	
335                    340                    345	
AAC ACG CCT TCC ACT GGG GAG CAG GAA GTC TCG GCT GGT TTA	1160
Asn Thr Pro Ser Thr Gly Glu Gln Glu Val Ser Ala Gly Leu	
350                    355                    360	
<hr/>	
TAAAACGAGG AGCAGTTTGA TTGTTGTTTA TAAAGGGAGA TAACAATCTG TATATAACAA	1220
CAAACCTCAA GGGTTTGTTG AACAAAGAA ACCTGTAAAG CAGGTGCCCA GGAACCTCAG	1280
GGCTGTGTGT ACTAATACAG ACTATGTCAC CCAATGCATA TCCAACATGT GCTCAGGGAA	1340
TAAATCCAGAA AAACCTGTGGG TAGAGACTTT GACTCTCCAG AAAGCTCATC TCAGCTCCTG	1400
AAAAATGCCT CATTACCTTG TGCTAATCCT CTTTTTCTAG TCTTCATAAT TTCTTCACTC	1460
AATCTCTGAT TCTGTCAATG TCTTGAAATC AAGGGCCAGC TGGAGGTGAA GAAGAGAATG	1520
TGACAGGCAC AGATGAATGG GAGTGAGGGA TAGTGGGGTC AGGGCTGAGA GGAGAAGGAG	1580
GGAGACATGA GCATGGCTGA GCCTGGACAA AGACAAAGGT GAGCAAAGGG CTCACGCATT	1640
CAGCCAGGAG ATGATACTGG TCCTTAGCCC CATCTGCCAC GTGTATTTAA CCTTGAAGGG	1700
TTCACCAGGT CAGGGAGAGT TTGGGAACTG CAATAACCTG GGAGTTTTGG TGGAGTCCGA	1760
TGATTCTCTT TTGCATAAGT GCATGACATA TTTTGTCTTT ATTACAGTTT ATCTATGGCA	1820
CCCATGCACC TTACATTTGA AATCTATGAA ATATCATGCT CCATTGTTCA GATGCTTCTT	1880
AGGCCACATC CCCCTGTCTA AAAATTCAGA AAATTTTTGT TTATAAAAGA TGCATTATCT	1940
ATGATATGCT AATATATGTA TATGCAATAT AAAATTTAG	1979

8/14

FIG. 3(A)





FIG. 3(B)



9/14

## FIG. 4(A)

MCP-1RA (CCR2-A)	MLSTSRSRFIRNTNESGEEVTTFFDYDYG--APCHKFDVKQIGAQLLPPL	48
MIP-1 $\alpha$ /RANTESR	M-----ETPNTTEDYDTTTEFDYGDATPCQKVNERAFGAQLLPPL	40
HUMSTR	MEGIS----IYTSNRYTEEMGS-GDYDSMK-EPCFREANANFNKIFLPTI	44
IL-8RA	MSNITDPQ-MWDFDDLNTGMPPADEY---SPC-MLETETLNKYVVIIA	45
IL-8RB	MESDSFEDFWKGEDLSNYSYSSTLPPFLDAAPC-EPESLEINKYFVVII	49
	48 1 69 79 2	
MCP-1RA (CCR2-A)	YSLVFIFGFVGNMLVVLILINCKKCLKLTDIYLLNLAISDLLFLITLPLW	98
MIP-1 $\alpha$ /RANTESR	YSLVFVIGLVGNILVVLMLVQYKRLKNMTSIYLLNLAISDLLFLITLPLW	90
HUMSTR	YSITFLTGIVGNGLVILVMGYQKKLSMTDKYRLHLSVADLLFVITLPLW	94
IL-8RA	YALVFLLSLLGNSLVMVILYSRVGRSVTDMYLLNLALADLLFALTLPW	95
IL-8RB	YALVFLLSLLGNSLVMVILYSRVGRSVTDMYLLNLALADLLFALTLPW	99
	101 115 3 136	
MCP-1RA (CCR2-A)	AH-SAAHEWVFGNAMCKLFTGLYHIGYFGGIFFIILLTIDRYLAIVHAVF	147
MIP-1 $\alpha$ /RANTESR	IDYKLKDDWVEGDAMCKILSGFYITGLYSEIFFIILLTIDRYLAIVHAVF	140
HUMSTR	AV-DAVANWYFGNFKCAVHVIMYTNLYSSVLILAFISLDRYLAIVHATN	143
IL-8RA	AA-SKVGWIFGTFLCKVVSLLKEVNFYSGILLACISVDRYLAIVHATR	144
IL-8RB	AA-SKVGWIFGTFLCKVVSLLKEVNFYSGILLACISVDRYLAIVHATR	148
	154 4 178	
MCP-1RA (CCR2-A)	ALKARTVTFGVITSVITMLVAVFASVPGIIFTKCKEDSVYVCGPYFP--	195
MIP-1 $\alpha$ /RANTESR	ALRARTVTFGVITSIIIMALAILASMPGLYFSKTQWEFTHHTCSLHFPHE	190
HUMSTR	SQRPRKLLAEKVYVGVMIAPALLTIPOFIFANVSEADDRYICDRFYPN-	192
IL-8RA	TLTQKR-HLVKFVCLGCMGLSMNLSLPFFLFRQAYHPNNSPVCYEV LGN	193
IL-8RB	TLTQKRYLVKFI-CLSLGLSLLLALPVLLFRRTVYSSNVSPACYEDMGN	197
	204 5 231	
MCP-1RA (CCR2-A)	--RGWNNFHTIMRNILGLVLPLLIMVICYSGILKTLLRCRNEKKRHRVAVR	243
MIP-1 $\alpha$ /RANTESR	SLREWKLFOALKNLFGVLPLLMIIICYTGIIKILLRRPNEKKS-KAVR	239
HUMSTR	--DLWVVVFQFQHIMVGLTLPGLVILFCYCIHISKLSHSGKHQKR-KALK	239
IL-8RA	DTAKWRMVLRLPHTFGFIVPLFVMLFCYGFTLRTLFAHMGQK-HRAMR	242
IL-8RB	NTANWRMLLRILPQSFGFIVPLLMFCYGFTLRTLFAHMGQ-KHRAMR	246
	244 6 268	
MCP-1RA (CCR2-A)	VIFTIMIVYFLFWTPYNIIVILLNTFQEF-FGLSNCESTSQDQATQVTET	292
MIP-1 $\alpha$ /RANTESR	LIFVIMIIFFLFWTPYNTILISVFQDF-LFTHCEQSRHLDAVQVTEV	288
HUMSTR	TTVILILAFACWLPPYIGISIDSFILLEIIKOGCEFENTVHKWISITEA	289
IL-8RA	VIFAVVLIFLLQWLPYNLVLLADTLMRTQVIQETCERRNNIGRALDATEI	292
IL-8RB	VIFAVVLIFLLQWLPYNLVLLADTLMRTQVIQETCERRNHIDRALDATEI	296

10/14

FIG. 4(B)

	295	7	313	
MCP-1RA (CCR2-A)	L	G	M	THCCINPIIYAFVGEKFRSLFHIALGCRIAPLQKPVCGGPGVVRPGKN 342
MIP-1 $\alpha$ /RANTESR	I	A	Y	THCCVNPVIYAFVGERFRKYLRLFHRRVA-----VHLVKW 327
HUMSTR	L	A	F	HCCLNPILYAFLGAKFKTSAQHALTS-----VSRGSS 325
IL-8RA	L	G	F	LHSCLNPIIYAFIGQNFHGFILKILA-----MHGLVS 327
IL-8RB	L	G	I	LHSCLNPLIYAFIGOKFRHGLLKILAIH-----GLIS 331
MCP-1RA (CCR2-A)	V	K	V	TTQGLLDGRGKGKSI GRAPEASLQDKEGA 374
MIP-1 $\alpha$ /RANTESR	L	P	F	LSVDRLE-RVSSTS-PSTGEHEL--SAGF 355
HUMSTR	L	K	I	LSKGK---RGGHSSVSTESSESS--FHSS 352
IL-8RA	K	E	F	LARH---RVTSYT-SSSVNVS---SNL 350
IL-8RB	K	D	S	LPKDS---RPSFVG-SSSGHTS---TTL 355



11/14

FIG. 5





FIG. 6



12/14

FIG. 7A







FIG. 7B




13/14

**FIG. 8B**

14/14

FIG. 8C



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/00476

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(6) : Please See Extra Sheet. US CL : 536/23.5; 435/320.1, 240.2, 69.1, 7.21; 514/12 According to International Patent Classification (IPC) or to both national classification and IPC																				
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 536/23.5; 435/320.1, 240.2, 69.1, 7.21; 514/12 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.																				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>																				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
X --- Y --- A	Cell, Volume 72, issued 12 February 1993, K. Neote et al., "Molecular Cloning, Functional Expression, and Signaling Characteristics of a C-C Chemokine Receptor", pages 415-425, especially the abstract and pages 415-418.	1, 4-7 ----- 3, 8 ----- 2, 9-14																		
Y --- A	Journal of Experimental Medicine, Volume 177, issued March 1993, G. Van Riper et al., "Characterization and Species Distribution of High Affinity GTP-coupled Receptors for Human Rantes and Monocyte Chemoattractant Protein 1", pages 851-856, especially the abstract.	3, 8 ----- 1, 2, 4-7, 9-14																		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X*</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*E* earlier document published on or after the international filing date</td> <td>*Y*</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*Z*</td> <td>document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means			*P* document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family																		
*O* document referring to an oral disclosure, use, exhibition or other means																				
*P* document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search 20 MARCH 1995		Date of mailing of the international search report 03 APR 1995																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer <i>Deborah Freese</i> DAVID L. FITZGERALD Telephone No. (703) 308-0196																		

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/00476

### A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C12N 15/12, 15/63, 5/10; C07K 14/715; G01N 33/68; A61K 31/00, 38/00

### B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

USPTO-APS; MEDLINE; BIOSIS; SCISEARCH; EMBASE; CAS; PASCAL

Search Terms: chemota?; monocyte, mcp; clon?, recombinant?, cDNA; jc; mouse, murine

Sequence databases: GENBANK/EMBL/DBJ; GENESEQ